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ABSTRACT
Biomaterials are used as templates for drug delivery, scaffolds in tissue 
engineering, grafts in surgeries, and support for tissue regeneration. Novel biomaterial 
composites are needed to meet multifaceted requirements o f compatibility, ease o f 
fabrication and controlled drug delivery. Currently used biomaterials in orthopedics 
surgeries suffer limitations in toxicity and preventing infections. Polymethyl methacrylate 
(PMMA) used as bone cement suffers from limitations o f  thermal necrosis and monomer 
toxicity calls for development o f better cementing biomaterials. A 
biodegradable/bioresorbable cement with good mechanical properties is needed to 
address this short coming. Metal implants used in fixing fractures or total joint 
replacement needs improvements in preventing biofilm formation and better tissue 
integration.
This research addressed the above mentioned research gaps by formulating novel 
biomaterial composites. Calcium phosphate cements are the alternative bone cements that 
are bioresorbable and promote tissue integration. These cements lack sufficient 
mechanical strengths to be used in load bearing sites. The addition o f nanoparticles is 
hypothesized to improve the mechanical properties without inducing toxicity to the 
tissue. This hypothesis was tested by evaluating compression and flexural strengths in 
addition to cytocompatibility tests. Results indicate that addition o f  nano-clay particles
(halloysites nanotubes) improved the compressive strength and osteoinductive properties 
o f  calcium phosphate cements.
To address the research need o f preventing implant failure due to infection and 
aseptic loosening, novel coatings are needed. Hydrogels are well establish for their ability 
to mimic in vivo environment, promote cell viability and as drug delivery vehicles. Use o f 
composites o f  hydrogels and drug-loaded nanoparticles to prevent infection was 
evaluated. Cytocompatibility results indicate good cell viability. Antibacterial results 
show sustained release o f  antibiotics from composite hydrogels and good zones o f 
inhibition on agar plates inoculated with bacterial cultures.
Fabricating a complex three-dimensional (3D) scaffold for tissue engineering was 
a huge challenge. With advancements in additive manufacturing, this research gap was 
addressed. Methods are needed to fabricate patient specific grafts made from 
biocompatible biomaterials. In this research, 3D printing was used as a platform to 
explore new biomaterials as grafts or scaffolds for tissue engineering. Computerized 
tomography scans were used to fabricate patient-specific grafts. The use o f calcium 
cements to fabricate three-dimensionally complex scaffold or grafts reported in this 
research holds potential in personalized medicine.
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CHAPTER 1 
INTRODUCTION
1.1 Regenerative Medicine in Orthopedics
The skeletal system o f the human body performs many vital functions, including 
support, protection o f  underlying tissues, maintain the structural framework, locomotion, 
mineral deposition, and hemopoiesis. Disease and trauma to this system primarily affect 
locomotion and hemostasis. Bone tissue has a remarkable potential to repair and 
regenerate. Minor injuries and acute diseases are treated with medication and 
conventional therapies. In cases o f severe injury and chronic diseases, the body’s repair 
mechanisms may not be sufficient enough for complete recovery. Regenerative medicine 
is used in such cases to aid faster repair and regeneration o f tissues. M odalities used to 
accomplish these functions include biomaterials, cells, signaling molecules, and tissue 
grafts mostly involving surgery [1],
Objectives o f orthopedic surgeries include bone fracture repair, placement o f  drug 
eluting implants, augmentation o f  osteoporotic bone, and jo in t replacement. An autograft 
taken from a patient’s own body is considered to be the gold standard for graft material. 
When the defect is too large to be replaced with available autograft material, biomaterials 
are used. Materials used in these surgeries other than living grafts are called biomaterials. 
In the case o f jo in t replacement surgeries, two types o f biomaterials are used. The joint 
implant is generally made o f  metals (titanium, cobalt, or alloys), and bone cements are 
used to fix the implant in place. The interface between the biomaterials and the tissues is
1
2critical for the success o f surgery. Hence, huge consideration is given to the physical, 
chemical and biological interactions o f these biomaterials with tissues. Implants have 
undergone constant modifications since their first use in the 1960s. Initially, the implants 
were metal alloys, and later they were modified to be porous for better tissue integration. 
In the 1980s, the implants were improved by coating with biocompatible and 
biodegradable material for better prosthesis attachment. Bone cements were used as 
grouting material to support the metal prosthesis. Owing to research suggesting implant 
failure due to bone cements, uncemented arthroplasties were developed. Aseptic 
loosening and biofilm formation on the implant surfaces are the main challenges faced in 
joint replacement surgeries [2],
Grafts for treating osteoporosis and spinal cord injuries are a in huge demand, 
with over 800,000 surgeries conducted annually [3]. To meet such high demand for bone 
grafts, tissue engineering and biomaterial sciences are the key. New biomaterials are 
being discovered along with modifications/improvements o f existing biomaterials every 
day.
1.2 Need for Novel Biomaterials
To develop better biomaterials, research must explore novel methods, 
technologies and materials. To improve the success o f implants and joint replacements, 
better tissue integration is desired along with ability to prevent infections. These 
improvements can be achieved using composites that combine antibiotic activity with 
osteoconductive properties. Biodegradable biomaterials are o f interest because they can 
eliminate the need for revision surgery. Biopolymers mimicking in vivo environment
3have strong potential as biomaterials. These polymers promote cell infiltration and 
attachment, resulting in better tissue integration.
Calcium-based bone cements hold the potential to replace currently used PMMA 
cements because o f their cytocompatibility, osteoconductivity, and resorbability. 
Calcium-based cements may contain calcium salts like sulfates, phosphates, and silicates 
[4], Application o f these cements are seen in orthopedic surgeries to fix fractured bones 
and non-load bearing surgeries like craniofacial and maxillofacial surgeries. Calcium- 
based bone cements are also used as drug carriers for localized and controlled drug 
delivery [5]. Orthopedic applications o f these cements are limited because o f its poor 
mechanical properties (like compression, tensile and flexural strengths) [6]. The 
mechanical properties o f calcium-based cements need to be improved to broaden their 
applications in orthopedic surgeries.
Hydrogels are biodegradable polymeric biomaterials that mimic in vivo 
environment. These biomaterials have a wide range o f applications, including drug 
delivery systems and tissue engineering [7]. Novel composite hydrogels can be prepared 
by addition o f biomaterials to meet specific research needs in orthopedics.
Nanoparticles o f  various forms are used as drug delivery systems. Nanotubes are 
one o f the nanoparticles used for sustained and targeted drug delivery. Halloysite 
Nanotubes (HNTs) and carbon nanotubes are used as drug carriers and biosensors [8, 9], 
Addition o f HNTs and other nanoparticles to polymeric matrices have improved 
mechanical properties [10], Novel composites can be prepared to meet various research 
needs with these nanotubes as they serve as drug carriers and improve mechanical 
properties o f the composites.
Tissue engineering o f grafts is a challenge owing to its complexity in physiology 
and geometry. Creating a 3D scaffold requires interdisciplinary research involving 
engineering, material science, and biology. Scaffold fabrication with desired porosity for 
cell migration and attachment can be challenging. Additive manufacturing is one 
promising method for fabricating scaffolds for tissue engineering. This technology allows 
the fabrication o f scaffolds with extreme precision, controlled porosity and geometry in 
three dimensions [11], Biodegradable scaffolds fabricated using additive manufacturing 
hold strong potential as grafts. Exploration o f additive manufacturing in biomedical and 
medical applications holds the potential for important advances.
1.3 Objectives
This research aims to develop novel composite biomaterials for orthopedic 
applications. The objectives, divided into three projects, are described in the Chapters 3,
4 and 5. Objectives for this research are as follows:
• To formulate and fabricate nano-enhanced calcium phosphate cements 
(CPCs), and to evaluate mechanical (compressive and flexural strengths), 
osteoconductive, and osteoinductive properties.
•  To create composite CPC and alginate hydrogels for implant coating, and to 
evaluate their cytocompatibility and antibiotic activity.
•  To 3D print patient-specific bone grafts and implants using inexpensive 
methods with CPCs and biodegradable polymers.
1.3.1 Nano-Enhanced Calcium Phosphate Cements
The objective o f  this project is to improve the mechanical properties o f calcium 
CPCSs by addition o f  nanoparticles. CPCs are osteoconductive cements, but their
5brittleness limits their usage in orthopedic surgeries. To improve their mechanical 
properties and improve their bioactivity, this project uses nanoparticles doped with 
biomolecules that promote differentiation o f bone marrow stromal cells into osteoblasts.
This project aims to formulate calcium phosphate cements with nanoparticles, and 
to evaluate their compressive and flexural strengths and their cytocompatibility. Calcium 
phosphate cements with improved properties are used in formulation o f novel hydrogels 
for biomedical applications.
1.3.2 Novel Calcium Phosphate Cement Hydrogels
This research project aims to develop composite hydrogels using CPCs and 
alginate hydrogels. These composite hydrogels are enhanced with drug loaded 
nanoparticles to prevent microbial growth. Addition o f  a few naturally occurring 
polymers will be evaluated for cytocompatibility and antibiotic activity.
Novel composite hydrogels will be fabricated in the form o f beads and films to 
show the ease o f  coating titanium and other implants. The hydrogel films will be tested 
for cytocompatibility. Antibiotic-loaded nanoparticles will be added to the hydrogels and 
tested to determine their effect against E. coli.
1.3.3 3-Dimensional Printing Patient-Specific Bone Grafts and Implants
The aim o f this project is to demonstrate the ability o f  additive manufacturing 
technology to fabricate patient specific grafts and implants. Computerized tomography 
scans o f  calcaneus bone are used to 3D print bone models in biodegradable polymers. 
Surface geometry o f right calcaneus bone and a mirrored left calcaneus will be evaluated. 
The accuracy o f  the 3D printed model will be evaluated by comparing modelled bone and 
3D printed bone.
6The objective o f this project is to fabricate patient-specific bone graft and/or 
implant with biodegradable biomaterials, also to demonstrate an inexpensive method to 
3D print CPCs. Accuracy and reliability o f  inexpensive 3D printers will be evaluated.
1.4 Dissertation Outline
This dissertation is comprised o f  six chapters. Chapter 1 gives a brief introduction 
to orthopedic surgeries and current treatment approaches using regenerative medicine. It 
also outlines the objectives o f  this research.
Chapter 2 gives an overview o f bone histology explaining cellular and 
extracellular components o f bones. It also discusses phases in bone repair and 
regeneration. This chapter also gives an overview o f the different components o f 
orthopedic surgeries: bone cements, metal implants, and bone grafts. HNTs, which are 
used to deliver drugs in this research, are also discussed.
Chapter 3 focuses on developing novel CPCs using HNTs and chitosan. It also 
discusses the improvements in compressive strengths and biological properties o f  novel 
CPCs. The basic foundation for this work was a part o f the group project with Dr. Karthik 
Tappa. Data obtained from a few experiments are shared with Dr. Karthik Tappa’s 
dissertation. Chapter 4 describes formulation and evaluation o f  composite hydrogels 
beads and films for coating implants. These composite hydrogels are evaluated for 
osteoconductivity and antibiotic activity. These two properties are essential for 
addressing the two important reasons for implant failure. The hydrogels project was also 
a part o f  the group work done with Dr. Sonali Karnik, and the data is shared in her 
dissertation.
7Chapter 5 explores the economical methods in fabrication o f patient-specific bone 
grafts using additive manufacturing. Geometrical comparison for similarities o f 
contralateral bones is analyzed in this chapter. Inexpensive methods to fabricate CPC 
scaffolds for tissue engineering using additive manufacturing is evaluated in this chapter. 
Chapter 6 reports the conclusion drawn from these research projects and discusses future 
work.
CHAPTER 2 
BACKGROUND
2.1 Histology of Bone
Since bone cements and orthopedic implants are used in and around bone tissue, 
their properties must mimic or support bone tissue. Bone is one o f the most metabolically 
dynamic tissues. Bones are constantly built and remodeled by the cells present in the 
tissue. Bones consist o f two zones, an outer cortical zone and inner trabecular zone. 
Cortical bone, also called compact bone, provides support while trabecular zone consists 
o f various pluripotent cells. Histology o f  bone tissue reveals abundant extracellular 
matrix and cells. Histologically, bones can be lamellar or woven (depending on cellular 
and extracellular matrix (ECM) organization). Both types o f bones essentially have the 
same cellular and extracellular components but at varied ratios and pattern.
2.1.1 Extracellular Matrix
Extracellular matrix is comprised o f  inorganic and organic components. Inorganic 
compounds contribute about half o f the extracellular matrix and are mostly calcium and 
magnesium salts. Calcium salts like calcium phosphate and hydroxyapatite (HA) are 
crystallized in a framework o f organic components. Organic components include 
collagen (type I), glucosaminoglycans, and glycoproteins. This organic extracellular 
matrix is called osteoid, in which the cells are scarcely dispersed.
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92.1.2 Cellular Components
The four types o f bone cells are:
• Osteoprogenitor cells
•  Osteoblasts
• Osteocytes
• Osteoclasts
Osteoprogenitor cells are mesenchymal stem cells that are found as spindle 
shaped cells close to the bone’s surface. These cells are mostly dormant in adults where 
there is no active bone formation. These cells, when stimulated by growth factors like 
Bone Morphogenetic Proteins (BMPs) and other chemicals, differentiate into osteoblasts. 
Osteoblasts are active cells that contribute to the formation o f organic matrix o f  bone. 
These cells actively synthesize collagen, glucosaminoglycans and glycoprotein forming 
new bone tissue. Once bone formation is complete, these cells differentiate into inactive 
osteocytes and are seen in the bone m atrix’s lacuna. In a fully grown bone tissue these 
cells are dormant. However, in cases o f fracture or other abnormal conditions, these cells 
can dedifferentiate into active osteoblast and contribute to bone formation.
As mentioned earlier, bone tissue is constantly formed and remodeled. Osteoclasts 
are other types o f  cells that erode bone by resorption o f minerals. These cells carefully 
erode a formed bone by lysosomal enzymes causing collagenous matrix’s hydrolysis 
followed by acidic hydrolysis o f minerals.
Parathormone and calcitonin are two hormones that regulate bone resorption. 
These hormones regulate calcium ions concentration in the blood. Parathormone, secreted 
by parathyroid gland, raises Ca++ ions level in the blood by stimulating osteoclasts that
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cause bone resorption and release free Ca++ into the blood stream. Osteoclasts activity is 
inhibited by calcitonin, which reduces blood Ca++ levels along with phosphate ion levels 
[12].
2.2 Bone Repair and Regeneration
Many tissues in the human body, including bone, can repair and regenerate in 
cases o f  injury. Several cellular and molecular pathways are involved in bone 
regeneration. The regeneration processes can be divided into the following stages 
according to Bab et al. (2013) [13]:
• Blood clotting and inflammatory stage
•  Granulation tissue formation
•  Bone resorption and remodeling
2.2.1 Blood Clotting and Inflammatory Stage
Immediately after exposure to trauma, pro-inflammatory cytokines such as 
interleukins (IL) and tumor necrosis factors (TNF) are released. These cytokines result in 
inflammation and promote blood clot formation. Blood clot formation is a vital step as it 
promotes cell migration and capillary budding at the site o f inflammation.
A wide range o f  cytokines are released during inflammation that attract cells to 
perform a specific function. ILs and TNFs along with colony-stimulating factors initiate 
repair pathways. Growth differentiation factor-8 is involved in recruiting mesenchymal 
stem cells to the site o f  injury promoting callus formation.
The healing process can be severely impaired in conditions with poor coagulation 
due to local or systemic conditions. The impaired blood clotting may be caused by
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genetic disorders, medication, and infection. The clot is gradually replaced by new tissue 
formation as repair progresses.
2.2.2 Granulation Tissue Formation
This phase is characterized by an abundance o f  mesenchymal stem cells at the site 
o f injury. These cells, upon exposure to the growth factors and differentiating agents 
released from the blood clot, undergo proliferation and differentiation. Mesenchymal 
stem cells are recruited from the periosteum, haversian systems, and bone marrow. These 
cells undergo differentiation and form new bone tissue by two mechanisms, 
intramembranous or endochondral ossification. These two mechanisms are seen in 
embryonic stages o f  skeletal development.
In intramembranous ossification pathway, osteoprogenitor cells and mesenchymal 
stem cells synthesize the hard callus forming bone directly. Endochondral ossification is 
characterized by cartilage formation by chondrocytes and subsequent mineralization to 
form bone.
2.2.3 Bone Resorption and Remodeling
Bone repair is characterized by bone formation and resorption. Osteoclasts and 
macrophages secrete proteolytic enzymes that remodel the bone. This activity o f 
osteoblasts is regulated by TNF-cr, Receptor Activator o f  Nuclear factor Kappa-B Ligand 
(RANKL), and Macrophage Colony Stimulating Factor (MCSF). The bone matrix 
formed in the granulation phase is extensively remodeled until the original shape and size 
o f the bone is formed.
The granulation phase and remodeling resemble the embryonic skeletal 
development, suggesting that bone repair and regeneration are similar to embryonic bone
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formation. Understanding the repair and regeneration o f  the bone helps in designing 
strategies that can accelerate key steps in healing and bone formation.
2.3 Bone Cements
Three o f  the most widely used biomaterials in orthopedic surgeries are bone 
cements, metal implants, and bone grafts. These biomaterials are implanted into the body 
to restore functionality at intended sites. Chronic health conditions (e.g. osteoporosis) and 
bone injuries (e.g. fractures) that cannot be treated with medicine can be treated by 
surgical methods. This approach o f  restoring functionality using implants and tissue 
engineering methods is often referred to as regenerative medicine [1]. Autografts and 
allografts o f  bones are considered as the best materials to be used in such cases [14]. 
However, because the material o f  appropriate size and shape is not always available and 
because the harvesting o f  the material introduces additional post-operative complications, 
synthetic biomaterials are preferred. Bone cements are commonly employed in treating 
various bone related issues such as fractures, osteoporosis, and joint replacement 
surgeries.
Bone cements are used in arthroplasties, vertebroplasties, craniofacial and 
maxillofacial surgeries. Arthroplasties are the surgeries involving joints, and they can be 
complete or partial joint replacement surgeries. Hip, knee, and shoulder are the most 
frequent jo int replacement surgeries [15], In these surgeries, metal implants are placed 
inside the bone and cements are used to hold the implants in place. As shown in Figure
2-1, the bone cements are subjected to compression, shear and flexural forces. They also 
need to have good adhesion with the implant and bone.
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Cement in tension 
Acetabulum cup
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Figure 2-1: Illustration o f  total hip replacement implant and various forces acting on 
the cement [16].
Compression fractures in the vertebral column can be caused by osteoporosis or 
trauma, and it can be severely painful. Surgical treatment is required to restore mobility 
to patients. These fractures are also common in cases o f cancers like multiple myeloma 
and giant cell tumor. Vertebroplasty and kyphoplasty are the two most commonly used 
surgical augmentation procedures to treat such types o f fractures. In both methods, bone 
cement paste is injected into the fractured bone using percutaneous injection [17, 18]. 
Bone cements in these surgeries are primarily subjected to compression forces and this 
research addresses this application in particular. In addition, bone cements loaded with 
chemotherapeutic agents that can control metastasis o f  tumors would be valuable.
Since its first use in 1950, PMMA has been widely used in orthopedic surgeries. 
Thermal necrosis, aseptic loosening due to volume shrinkage, and monomer toxicity are 
concerns that prompted research for novel bone cements [19]. Use o f  calcium cements in
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orthopedics is limited to non-load bearing surgeries because these cements have poor 
mechanical properties. These cements show good biocompatibility and osteoconductivity, 
and hence used as grafts or substitutes.
2.3.1 Generations o f Bone Cements
Bone cements or biomaterials were classified into generations based on their 
properties. According to Navarro et al. bone cements are classified into three generations 
as follows.
2.3.1.1 First Generation
First generation bone cements have the key property o f being inert in vivo. These 
materials do not initiate any immune response once implanted into the human body. This 
property is one o f  the prime requirements for any biomaterials. Polymeric and acrylic 
bone cements like PMMA and Polyethyl ether ketone (PEEK) are classical examples o f 
this class [20].
PMMA is one o f the most widely used bone cement materials. Apart from being 
inert, it has good mechanical properties. Compressive strengths o f various formulations 
can range from 66 MPa to 111 MPa, while tensile strength range from 32 MPa to 38 MPa 
[21- 23]. PMMA consists o f two parts; a powdered polymer is mixed with liquid methyl 
methacrylate monomer. These two components are mixed to form a paste that sets into a 
hard mass exothermically via polymerization. The production o f heat is one o f the main 
limitation o f  PMMA, and while setting, temperatures can rise up to 100°C [24]. Another 
limitation is toxicity o f  unreacted monomer [25]. To overcome these two limitations, new 
biomaterials were proposed to replace PMMA.
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2.3.1.2 Second Generation
Second generation bone cements have additional attributes o f  being bioactive and 
biodegradable. The bioactive property is defined as the ability to enhance biological 
response o f the tissue. It may promote cells to form new bone tissue, or it may provide 
favorable conditions for cell proliferation or survival. Eventually, these cements are 
replaced by new bone tissue. These cements may degrade at different rates, depending on 
their composition [20]. CPCs are good examples o f this generation. Use o f  these cements 
is limited to non-load bearing sites because they have poor mechanical properties 
(compression, flexural and tensile strengths).
2.3.1.3 Third Generation
Third generation bone cements are tailored to stimulate the desired responses at 
implantation sites. These materials can stimulate specific cellular responses and have the 
properties o f second generation cements. They are also bio-absorbable, meaning cells 
can take up these materials upon stimulation to synthesize the required matrix/proteins 
that form the bone tissue. Examples for this class are cements that are loaded with 
biochemicals and growth factors [26], Second generation cements are often loaded with 
growth factors to induce differentiation o f cells to osteoblastic phenotypes. BMPs are the 
most commonly used differentiating agents. Other agents employed are ascorbic acid, P- 
glycerophosphates and dexamethasone (Dex) [27].
2.4 Metal Implants
Osteoporosis, arthritis, and trauma can be severe, causing patients immobility and 
pain. Orthopedic surgeries are performed to alleviate pain and improve the living 
conditions o f  these patients. Metal implants used in these surgeries can range from simple
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plates and screws to total joint prostheses. Total joint replacement surgeries are common 
surgeries which mostly include metal implants (or prosthetic joints). Metal implants are 
generally fabricated from inert metals like stainless steel, titanium, niobium, and their 
alloys. Titanium is the most widely used metal in total joint replacement implants 
because o f  its biocompatibility and strong mechanical properties [28].
These metal implants are surgically placed in the patients with or without bone 
cements. Even though success o f these surgeries are good, revisions are common.
Implant failures are primarily caused by aseptic loosening, infection and implant fracture 
[29, 30],
Current methods to prevent infection include coating implants with antibiotics, 
mixing bone cements with antibiotics, and using antibiotics following surgery. These 
procedures have certain limitations and severe side effects [31]. To prevent aseptic 
loosening, implants coated with HA, hydrogels, and biomolecules [32].
2.5 Bone Grafts
To restore normal structure and function o f  damaged bones, bone grafts are used. 
Bone grafts can be autografts, allografts or xenografts. Autografts are pieces o f  bone 
harvested from the patient’s own bones like the iliac, sternum, and femur. Autografts are 
the best grafts as they do not induce immunological reaction and they promote bone 
growth. Hence, these grafts are considered the gold standard. Applications o f autografts 
are limited because o f patient morbidity and availability. Allografts are also bone grafts 
that are harvested for other individuals. Allograft use is limited owing to the risk o f  non­
union, infection, and/or rejection.
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With advancements in biomaterials and tissue engineering, bone graft constructs 
are fabricated, and are used as bone grafts. Bone grafts are engineered to have the 
properties o f osteogenesis, osteoconduction, osteoinduction, and osteointegration. Bone 
grafts fabricated with different biomaterials were shown to have good potential. Acellular 
and cellular systems in combination with growth factors and angiogenetic factors were 
also used as bone grafts [33].
The advantages o f  tissue engineered bone/synthetic grafts are non-immunogenic, 
readily available, and the ability to choose from a wide range o f biomaterials to meet 
patient specific needs. Synthetic bone grafts are fabricated with biopolymers, bioglass, 
calcium phosphate cements, aluminum oxide, and hydroxyapatite. These grafts are 
available in various forms like pellets, granules, cement paste, and blocks. Appropriate 
grafts are chosen by the surgeons to fulfill a patient’s needs [34],
2.5.1 Patient Specific Bone Grafts
Images from CT/Magnetic Resonance Image (MRI) scans were used to develop 
anatomically shaped alloplastic scaffolds. The scaffolds were seeded with host cells and 
growth factors to develop grafts with living tissue. The patient specific bone grafts were 
advantageous over conventional methods o f  treatment. In absence o f these “designer 
scaffolds,” the surgeons have to shape the bone graft materials according to the defect 
and perform the surgery [35]. Shaping bones, especially facial bones, can be difficult and 
time consuming because o f  their complexity in geometry for every patient. Previous 
studies have modelled and fabricated grafts for bone and cartilage using biodegradable 
biomaterials. Injection molding and Computer Numerical Control (CNC) milling were 
employed in the fabrication process [36], Challenges in fabrication o f  models using these
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methods are reliability, reproducibility, and fabrication time. Cost is an important factor 
in using fabricated grafts [35].
2.6 Halloysite Nanotubes
HNTs are aluminosilicate sheets rolled up as hollow tubes o f 0.5 to 5 pm length 
with luminal diameter o f 15-100 nm. As the sheets roll up to form tubular structures, the 
outer surface has silica, giving it a negative charge, and inner lumen has alumina, giving 
it positive charge as shown in Figure 2-2. This lumen can be loaded with drugs and other 
bio-molecules for extended release [37]. The charge on the outer surface and inner lumen 
affects the efficiency and ease or loading drugs/chemical agents. Substances with overall 
negative charge can be easily loaded into the lumen compared to positively charged 
molecules.
Silica (SiOj)
Figure 2-2: Halloysites nanotubes. A) Transmission electron micrograph o f  HNTs. 
B) Illustration o f HNTs.
HNTs are used in various applications for preparation o f nanocomposites to 
improve polymer properties such as thermal stability, flame retardant, and mechanical
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properties (fracture toughness, compression, and flexural modulus) [8]. HNTs were used 
in the fabrication o f many scaffolds for tissue engineering. These scaffolds showed 
improved surface properties, porosity and mechanical properties [38].
Ready availability, biocompatibility, and cost effectiveness o f  HNTs have 
promoted their use in various fields o f biology. HNTs are used as carriers for drug and 
gene delivery. Surface o f HNTs were functionalized with 3- (Aminopropyl) 
triethoxysilane, and attached with antisense oligonucleotides. Results suggest that HNTs 
improve intracellular delivery o f genes and antitumor activity [39].
Layer-by-layer self-assembly was used to modify HNTs to deliver two drugs 
using the same nanoparticles. The first drug was loaded into the lumen o f HNTs and 
coated with poly electrolytes. The second drug was coated on to the poly electrolyte 
layers. This method o f  having two drugs in the same delivery system is critical in treating 
drug resistant infections and cancers [40].
Extended and sustained delivery o f  various drugs including antibiotics, 
chemotherapeutics, antifungal, and growth factors was observed from doped HNTs. 
Scaffolds fabricated with HNTs doped with various bioactive molecules had extended 
elution profiles [41,42, 43]. Extended and localized drug delivery o f  these bioactive 
molecules are desired as it prevent systemic side effects o f  the drugs. HNTs were 
documented to be biocompatible with no toxicity in the rat dermal model [44].
CHAPTER 3
NANO-ENHANCED CALCIUM PHOSPHATE CEMENTS
3.1 Introduction
3.1.1 Calcium Phosphate Cements
CPCs contain various forms o f calcium and phosphate. Examples include 
calcium phosphate monobasic (MCP), anhydrous calcium diphosphate (DCPA), calcium 
diphosphate dehydrate (DCPD), HA, a-tri-calcium phosphate (a-TCP), (l-tri-calcium 
phosphate (P-TCP), calcium tri-phosphate (TCP), tetra calcium phosphate (TTCP), and 
amorphous calcium phosphate [45, 46], These cements are prepared by mixing two or 
more components o f calcium and phosphate salts and adding a setting liquid. Various 
setting liquids in various concentrations were used to formulate best CPCs. Many 
aqueous solutions are used as setting liquids. Commonly employed liquids are disodium 
phosphate (Na2HP04), water, saline solution, and chitosan [14]. These calcium and 
phosphate salts precipitate out as crystals o f  hydroxyapatite or dicalcium phosphate in the 
added liquid and set into a hard mass as cement. Depending on the final product formed 
after setting, CPCs are classified as apatite or brushite cements [47], The following 
chemical reactions explain the formation o f  apatite and brushite cements [48]:
2Ca4(PO4)2O+2CaHPO4^ Cai0(PO4)6(OH)2. Eq. 1
P-Ca3(P 0 4)2 + Ca(H2P 0 4)2.H20  +7H20  ^ C a H P 0 4.2H20 . Eq. 2
2 0
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E q . l  describes the formation o f  apatite when equal moles o f TTCP (Ca4(P0 4 )2 0 ) 
and DCPA (CaHP04). This reaction supports formation o f apatite cements. P-TCP (p- 
Ca3(P 0 4)2 ) and MCP (Ca(H2P04)2.H20) react in an aqueous environment and precipitate 
DCP as explained by Eq. 2. This reaction occurs during the setting phase in brushite 
cements.
Apatite cements have HA as their product. These cements are stronger and 
degrade at a slower rate. Brushite cements on the other hand, have DCPA as their setting 
product and degrade at a faster rate [14].
These cements are biocompatible and osteoconductive, but have poor mechanical 
properties. To enhance mechanical properties, many polymers were added to solid and 
liquid phases o f CPCs [14, 49]. These polymers also improved certain properties like 
setting time, cohesion, injectability, porosity, and bioactivity.
3.1.2 Chitosan
Chitosan is a biocompatible and biodegradable polysaccharide. Chitosan is 
insoluble in many solvents because o f extensive hydrogen bonding and semi crystalline 
structure. Many derivatives o f chitosan were synthesized to enhance its solubility in 
neutral aqueous solvents. To produce this polymer, crustacean shells are processed to 
obtain chitin, which is further processed by deacetylation. Chemically, chitosan is a 
polymer o f  glucosamine as shown in Figure 3-1.
2 2
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Figure 3-1: Chemical structure o f  chitosan. Monomer units containing D-glucosamine.
Chitosan is widely used in tissue engineering o f bone and cartilage because it has 
excellent biocompatibility and osteoconductivity, and it promotes cell attachment and 
proliferation. It is used in preparation o f  hydrogels and scaffolds in combination with 
other natural polymers [50]. It also has fungistatic and hemostatic properties [51]. The 
addition o f this polymer to CPCs resulted in enhanced compressive and flexural strengths 
along with a decrease in setting time [14] and imparting anti-washout property [52]. 
Compressive strength o f  CPCs were improved from 2.6 MPa to 12.5 MPa for the best 
formulations [53]. When placed in an aqueous environment, CPCs generally tend to 
dissolve or precipitate as calcium and phosphate salts. The addition o f certain polymers 
can retard or stop CPCs from being washed out or precipitated; this property is called 
anti-washout or cohesiveness. Chitosan lactate was used in the fabrication o f  CPCs for 
this research.
3.1.3 Nanoparticles and Bone Cements
Research was directed in enhancing the mechanical properties o f  bone cements 
(both PMMA and CPCs) by adding the nanoparticles. Fillers o f different particle sizes 
were added to PMMA and a relation was found between the size o f  particles used and the
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mechanical properties. Fillers are the substances added to cement for altering physical 
properties (rheological for instance). Barium sulfate is used in PMMA cements to 
visualize it in vivo under X-Rays. Commercially available PMMA has barium sulfate in 
micron dimensions. When the particle size o f barium sulfate was reduced to nanometers, 
compressive strength increased from 47 MPa to 52 MPa [54]. It is hypothesized that an 
increase in fatigue strength is due to energy dissipation. Bone cements generally develop 
small cracks within them. When a crack is obstructed by a particle, the stress is absorbed 
by that particle and thus propagation o f the cracks is inhibited. As nanoparticles (of 
barium sulfate) were evenly and densely distributed, they reduced crack propagation and 
strengthened the cement [54],
Effect o f  nanoclay addition to PMMA was explored by Wang et al. (2008). 
Addition o f  nanoclay increased fracture load o f  a PMMA-HA composite. When PMMA- 
HA composite was formulated, the presence o f HA reduced fracture load o f  PMMA 
cement. To compensate for the decrease, research was performed using nanoclay. The 
results indicated that addition o f 1% w/w o f nanoclay restored the PM M A-HA’s fracture 
load to that o f  normal PMMA cement [55].
Multi-walled carbon nanotubes (MWNT) were added in small proportions to 
PMMA to observe any changes in mechanical properties. The research indicated that 2% 
w/w o f MWNT in PMMA improved fatigue strength o f  the cement [56]. MWNT were 
also hypothesized to inhibit crack propagation within the PMMA matrix that could have 
formed from unequal distribution o f  materials or voids in PMMA after setting.
A similar trend o f  increase in mechanical properties (compressive modulus, and 
compressive stress) was observed in fabrication o f  chitosan-HNT scaffolds [38]. In vitro
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experiments were done to confirm HNTs incorporated scaffolds’ cytotoxicity on mouse 
fibroblast (NIH3T3) cells. Results indicated that the presence o f HNTs was not toxic for 
the cell line used [38].
3.1.4 Dexamethasone
Dexamethasone (Dex) is a synthetic glucocorticoid used as a steroidal anti­
inflammatory and immunosuppressive drug, commonly used in treating allergies and 
auto-immune diseases. Dex induces differentiation o f cells into osteoblasts and promotes 
mineralization [57]. Studies o f Dex-induced differentiation concluded that it acts through 
activation o f Runx2 genes. Runx2 genes transcribe factors that regulate osteogenesis by 
promoting Alkaline Phosphatase (ALPase) and other markers like osteopontin, 
osteocalcin, and bone sialoprotein [58].
Dex’s inductive effect on osteoblasts was seen at concentrations from 10'5 to 
10"11 M with a maximum effective range o f  10'6 to 10"9M [58] [59], When Dex is used in 
pharmacological dosage for a long period o f  time (longer than 6 months), it can induce 
osteoporosis [60]. This induction is one o f the serious side effects o f  using this drug for 
chronic conditions. Dietary supplements and other medications are available to treat 
gluco-cortieoid induced osteoporosis [60].
3.1.5 Objective and Rationale
CPCs have good biocompatibility, biodegradability, and osteoconductivity, but 
their usage is limited because o f  their poor mechanical properties. This research attempts 
to enhance their mechanical properties and enhance osteoinductive properties. Addition 
o f these properties to CPCs would broaden their application in surgeries involving load 
bearing sites. Enhanced mechanical properties and an osteoinductive nature can be
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incorporated in CPCs in one step using HNTs. HNTs with their nano particle dimensions 
can improve mechanical properties; the HNT lumen can be loaded with a wide range o f 
drugs/growth factors that can induce differentiation o f osteoblasts. HNTs also provide 
sustained release o f  drugs/growth factors that can accelerate mineralization and faster 
healing by new bone formation. The hypothesis for this research is:
1. Addition o f  nano-particles (HNTs) to CPCs will enhance compressive and 
flexural strengths.
2. Dex loaded in HNTs will promote osteoblast differentiation and bone 
mineralization.
3.2 Materials and Methods
3.2.1 Materials
Different calcium salts were used in a pilot study to determine the best 
formulation. In this pilot study, calcium phosphate monobasic monohydrate (MCPM- 
Ca(H2P04)2.H20) calcium phosphate dibasic anhydrous (DCPA- CaHPO-i), P-tri calcium 
phosphate (P-TCP- Ca3(P04)2), polycaprolactone (PCL- (C6Hio02)n), calcium L-lactate 
(C6HioCa06.xH20) were used and bought from Sigma-Aldrich, St. Louis, MO. Tetra 
calcium phosphate (TTCP- Ca4(P04)20) was ordered from CaP Biomaterials, E. Troy, 
WI. Different setting solutions were prepared using sodium phosphate dibasic (Na2HP04- 
Fisher Scientific Company, Waltham, MA), chitosan oligosaccharide lactate, chitosan 
(low molecular weight), bought from Sigma-Aldrich, St. Louis, MO.
Two or more calcium salts were mixed with various setting liquids and were 
evaluated for anti-washout property and compressive strengths. The formulation that had
the best anti-washout property and good compressive strengths was chosen, and HNTs 
were added to it in different wt. % ratios and was further subjected to cell cultures assays.
For the compression test, cylindrical shaped specimens were made o f  dimensions, 
12 mm in length and 6 mm in diameter. These dimensions are in accordance with ASTM 
F451 standards for acrylic cements. Specimens after setting were tested for compressive 
strength using ADMET expert 2600 universal testing machine with a load speed o f 1 
mm/min.
For flexural testing, specimens o f  dimensions 65 x 10 x  4 mm were fabricated 
and subjected to a three-point bending test. The distance between consecutive points was 
set to 20 mm, and load speed was 0.75 mm/min. The ADMET expert 2600 universal 
testing machine was used to perform the flexural test. Illustration o f the bending test is 
shown in Figure 3-2.
Figure 3-2: Three-point bending test for measuring flexural strength o f  CPCs.
Flexural strength o f  CPCs was measured using the formula shown in following 
equation:
3.2.2 Physicochemical Analyses
d \
L
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Here a  is the flexural strength; F is the peak force; L is the total distance between 
3 points; b is the width o f  the specimen; d  is the height o f  the specimen. Flexural 
strengths o f dry specimens were measured.
Scanning electron microscopy (SEM) was used to analyze the surface o f  CPCs. 
Specimens fractured during compression test were taken for SEM imaging. S4800 Field 
Emission SEM, HITACHI was used for our research. A gold nano layer (about 3 nm) 
was laid over specimens before SEM analysis.
Fourier Transformation Infrared (FTIR) spectroscopy was used to analyze the 
composition o f  CPCs after setting. The potassium bromide (KBr) pellet method was used 
for FTIR spectroscopy. A small amount o f KBr was placed into the die set to form a thin 
discs o f  KBr, and these discs were subjected to a pressure o f 8 tons. This pressure made 
the KBr to re-crystallize to form thin transparent discs that were used to obtain the 
background spectrum. A measured amount o f test sample powder was added to KBr and 
thin discs were prepared by the same procedure.
3.2.3 Cell Cultures and Staining
Two scaffold types were made for culturing cells. One set o f scaffolds were made 
to evaluate the osteoconductive nature o f  CPCs while the other set for osteoinductive 
property.
Osteoconductive scaffolds contained CPC powder with varied amounts o f  HNTs. 
Four groups were prepared containing 0%, 5%, 10%, and 15% wt. o f HNTs to CPC 
powders. These HNTs were not loaded with Dex or any other growth factors. Mouse pre­
osteoblast cell lines MC3T3 - E l  (ATCC® CRL-2593™) were used for seeding on these 
scaffolds to evaluate the osteoconductive property o f the fabricated CPCs.
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To evaluate osteoinductivity o f  the formulation using Dex, four sets o f scaffolds 
were prepared. The solid phase containing powders were prepared in the following 
combinations:
Group 1: CPC powder without HNTs,
Group 2: CPC powder with 10% wt. HNTs,
Group 3: CPC powder with 5% wt. Dex doped HNTs and 5% wt. plain HNTs, 
Group 4: CPC powder with 10% wt. Dex doped HNTs.
Mouse bone marrow stromal cells (BSCs) (ATCC® C R L-12424™) were used to 
evaluate the osteoinductive nature o f  these groups o f CPCs. Scaffolds for both sets were 
thin discs o f  2 mm thickness and 10 mm in diameter. Sterile autoclaved water was used 
to prepare chitosan lactate solution and molds were sterilized with ethanol. After the 
scaffolds were prepared, before seeding cells onto them, they were immersed in 95% 
ethanol for 5 min and air dried under the hood for sterilization.
Cells were seeded onto the scaffolds and were analyzed for collagen, acidic 
mucopolysaccharides and ALPase activity. For osteoconductive scaffolds, these assays 
were done on 7th and 14th day and for osteoinductive scaffolds, assays were done on 1st, 
3rd, 7th, and 14th day after seeding them. Picrosirus Red (PSR) stain was used to stain 
collagen, Alcian Blue (AB) was used to stain acidic mucopolysaccharides, and ALPase 
assay was done to evaluate the differentiation o f cells into osteoblastic cells.
3.2.3.1 Picrosirus Red Staining
Media was removed from the wells and a wash was given with Dulbecco’s 
phosphate buffered saline (DPBS) before fixing the cells using 95% ethanol. These fixed 
cells were stained with PSR to quantify the amount o f collagen secreted. The staining kit
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had three different solutions. Solutions A and B were Picrosirus stain and Solution C was 
Hydrochloric acid. Solution A was added to the cells and removed after 5 minutes, and 
Solution B was added and then removed after an hour. A wash was given with Solution C 
to remove excess staining. Glacial acetic acid, 7% v/v aqueous solution was used as de­
stag ing  solution. As the CPC scaffolds were too thick for light to penetrate, microscopic 
imaging and quantification was difficult. To quantify staining, de-staining was used and 
measured for staining dye concentration using UV-Visible spectrophotometer (Thermo 
Scientific Nano Drop 2000c).
3.2.3.2 Alcian Blue Stainine
Cells were fixed through the method mentioned earlier, and AB staining solution 
was added and removed after 10 minutes. Excess stain was washed with DPBS and de- 
staining solution (7% glacial acetic acid) was used to measure the amount o f  stain taken 
up by cells. UV-Visible spectrophotometry was used to quantify the amount o f  AB in de- 
staining solution.
3.2.3.3 ALPase Assay
A marker specific for differentiated osteoblasts was measured to evaluate the 
differentiation o f  MSCs towards osteoblastic lineage. Alkaline phosphatase is a 
characteristic enzyme for osteoblast cells. Its presence can be determined by its ability to 
break down phosphate groups from its substrates. BCIP/NBT assays were used to 
estimate ALPase activity. (5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue 
tetrazolium) is the substrate in this assays which, when acted upon by ALPase, gives a 
purple stain. Protocol supplied by the manufacturer was followed to determine ALPase
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activity. Glacial acetic acid 7% was used as de-staining solution to quantify ALPase 
activity.
3.2.4 HNTs Loading
HNTs were loaded using vacuum loading technique [37]. A saturated solution o f 
Dex was made by dissolving 200 mg o f Dex in 50 mL ethanolic water (50%v/v). To this 
solution, 9 g o f HNTs were added and subjected to vacuum cycles. The suspension o f 
HNTs in Dex was kept in vacuum for 20 min and at atmospheric pressure for 20 min; this 
was repeated thrice. This suspension was left under vacuum overnight and centrifuged. 
The supernatant was discarded and HNTs were washed twice with deionized water to 
remove the drug adsorbed on HNTs surface. Washed HNTs were dried in vacuum and 
these were used in further experiments.
Drug release from HNTs was measured for a period o f 96 hours. In a centrifuge 
tube, 1 mL o f simulated biological fluid (SBF) was added to 50 mg o f Dex, and the tube 
was placed in a shaker. After specific time intervals, the tube was centrifuged to 
precipitate HNTs, and the supernatant was collected. An equal volume o f  SBF was 
replaced every time the supernatant was collected to maintain sink conditions. Collected 
supernatant was observed under UV-Visible spectrophotometer at a wavelength o f  240 
nm.
3.3 Results and Discussion
3.3.1 Compression Strength
Specimens made for compression test were analyzed for maximum compressive 
strength, and peak load taken before they fractured. O f various combinations o f  calcium 
salts and setting liquid salts, the ones which had anti-washout property and good
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compressive strength were chosen. Most o f the samples had decent compressive strength 
(up to 14 MPa) when dry, but upon placing them in aqueous environment, they became 
soft and collapsed.
Specimens made with TTCP and DCPA using chitosan as the setting liquid had 
good mechanical properties. As chitosan is soluble only in acidic solutions, aqueous 
solution o f chitosan in acidic water was used. The acidity resulted in elution o f acid into 
SBF while testing for their anti-washout property. The pH o f SBF is typically maintained 
at 7.40, but when these samples were placed, the pH o f SBF was raised to as high as pH 
2.0. Hence, in-spite-of their good mechanical properties, these samples were not selected 
because the acidity required for elution would create hostile environment for cells. To 
prevent cytocompatibility issues, chitosan lactate was used as setting liquid as it was 
soluble in neutral water.
Hence, the best composition with desired properties was equimolar mixture o f 
TTCP and DCPA in the solid phase with chitosan lactate as the liquid phase. Different 
concentrations o f HNTs were added to this composition. These compositions were tested 
for compression and flexural strengths.
Figure 3-3 compares stress-strain curves o f  CPCs added with different ratios o f 
HNTs. The stress-strain curves for CPCs are similar to brittle materials. Bone is 
considered quasi-brittle, exhibiting both brittle and ductile properties [61]. CPCs with 5% 
wt. HNTs had a different curve compared to the other groups. CPCs with 10% and 15% 
wt. HNTs had similar pattern, exhibiting a sharp failure point near a strain o f 0.1. 
Addition o f  HNTs significantly changed the compressive strengths o f  CPCs, as seen in 
Figure 3-4.
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Figure 3-3: Stress-strain graph for CPCs with varying amounts o f HNTs.
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Figure 3-4: Compressive strength o f CPCs with varying amount o f HNTs. Error bars 
are standard deviation, n  =  5.
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Peak compressive strength was seen in groups that were added with 5% wt.
HNTs. Peak compression pressure o f  16.5 ± 1.0 MPa was observed for CPCs that were 
added with 5% wt. HNTs. CPCs that were not added with HNTs had a compressive 
strength o f  11.7 ± 2.2 MPa. Compressive strength o f CPCs increased by 41.5% upon 
addition o f  5% o f HNTs. At concentrations o f 10% and 15% wt. HNTs, compressive 
strength o f  CPCs was recorded as 14.4 ± 1.6 MPa and 13.5 ± 1.7 MPa.
A minimum o f 5 samples in each group were tested and statistical analysis was 
performed on the data sets. One-way ANOVA was done to analyze statistical 
significance among the four groups. Results suggest a statistically significant difference 
in the means o f all four groups at a  = 0.05. Post hoc analysis was done to identify the 
group with the highest mean compressive strength. Results from Tukey’s HSD suggest 
that groups containing 5% wt. HNTs have the highest mean compressive strength.
The addition o f  nanoparticles in the matrix o f  CPCs improve compression 
strength up to certain concentration. Beyond this concentration no significant 
improvement was observed. The optimal concentration for this composition was 
observed to be at 5% wt.
Particle size o f  TTCP contributes an important role in determining the 
compressive strength o f  CPCs. Smaller particles attribute for increased strength 
compared to larger particles. As shown in Figure 3-5, at particle size o f  1.9 ± 0.3 pm the 
compressive strength o f  CPCs was 23.5 ± 1.4 MPa. Larger particles with a diameter o f
4.1 ± 1.2 pm  had a peak compression strength o f 8.3 ± 2.6 MPa. Particles with an average 
diameter o f  2.4 ± 0.4 pm  had a compression strength o f 17.6 ± 1.1 MPa. Smaller particles
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may be arranged in a compact manner, resulting in smaller voids between the particles 
and thus greater compression strengths o f  CPCs.
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Figure 3-5: Compression strength as a function o f  particle size o f  TTCP. Error bars are 
standard deviations, n  =  5.
This improvement in compression strength by the addition o f HNTs is useful in 
applications where the primary forces acting on cements is compression. Bone cements 
used in vertebral augmentation are primarily subjected to compressive forces, and these 
novel CPCs can be used in such surgical procedures.
3.3.2 Flexural Strength
A three point bending test was performed to evaluate flexural strength o f  CPCs. 
Flexural strength o f  a control group containing just DCPA, TTCP and chitosan lactate 
was recorded as 13.9 ± 2.5 MPa. Addition o f  HNTs at 5% wt. improved the strength to
17.1 ± 2.5 MPa, but this increase was not statistically significant at a  = 0.05. CPCs 
containing 10% and 15% wt. FTNTs had flexural strength o f 15.4 ± 0.3 MPa and 17.4 ±
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1.5 MPa, respectively. This trend o f  flexural strengths is graphically represented in 
Figure 3-6.
15%
£
t  10%c
3o
Ea
£  5%
0%
i------ 1
5 10 15
Flexural strength (MPa)
20
Figure 3-6: Flexural strength o f  CPCs. Error bars are standard deviations, n — 3.
The error bars represent standard deviation in the samples. This deviation may be 
attributed to air gaps formed while preparing the bone cement and loading it into the 
molds. The presence o f air pockets can reduce the compression and flexural strength o f 
cements. These pockets can be avoided if  the specimens are mixed and prepared in a 
vacuum chamber.
3.3.3 Surface Topography
SEM images were analyzed to evaluate surface topography o f  CPCs. Cell 
viability and cell proliferation largely depend on the substrate surface. Rough surfaces 
improve cell attachment and further viability. SEM images o f  CPCs clearly indicate 
rough surfaces that provide a conducive environment for cell viability. As seen in F igure
3-7, granular particles o f  DCPA and TTCP are present in a matrix o f chitosan lactate.
Figure 3-7: Scanning electron micrographs o f  CPCs. A) SEM o f control CPC with no 
HNTs at 1200 x  magnification. B) SEM o f CPC with 5% wt. HNTs at 1200 x 
magnification. C) SEM o f CPC with 10% wt. HNTs at 1500 x  magnification.
D) SEM o f CPC with 15% wt. HNTs at 1500 x  magnification [62].
Chitosan lactate is seen as flakes or scales as a thin layer around particles o f 
DCPA and TTCP. Instances o f  HNTs were observed in few images distributed as clumps 
and as fine particles. As seen in Figure 3-8, clumps o f HNTs are distributed in the matrix 
o f  CPCs, filling the voids between the particles.
This distribution and filling o f voids increases the mechanical strength by 
preventing crack propagation. These nanoparticles deflect or absorb a propagating crack, 
thus preventing formation o f weak points and improving strengths.
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Figure 3-8: Scanning electron micrograph o f  CPC added with 5% wt. HNTs showing 
clump o f HNTs.
3.3.4 FT-IR Analysis
The setting product o f apatite cements was hypothesized to be hydroxy apatite. To 
evaluate the end product formation, FT-IR was used. Figure 3-9 compares IR spectra o f 
CPCs with 5% HNTs, control CPCs without HNTs, and hydroxy apatite. Three samples 
from each group were analyzed, and the average was plotted. Band o f peaks seen at a 
wavenumber o f  900-1200 cm '1 are due to P 0 43- groups present in all the test samples. 
Peaks at 1450 cm '1 are characteristic o f C032- groups found in HA. Peaks at 3100- 3700 
cm '1 are caused by -O H  groups HA [63].
CPCs with HNTs have stronger -  OH peaks than the control CPCs. The stronger 
peaks could arise because the presence o f nanoparticles acted as seeding agents 
facilitating precipitation o f  HA crystals.
38
140
120
r"
100 g
0
4000 3500 3000 2500 2000 1500 1000 500
W avenum ber (cirr1)
 CPCs with HNTs  C P C s  HydroxyApatite
Figure 3-9: FTIR spectra o f  HA, CPCs with and with HNTs. n  =  3.
3.3.5 Dexamethasone Elution
Drug elution was studied using 50 mg o f Dex-loaded HNTs. The release profile 
is shown in Figure 3-10. A burst release from HNTs occurs during the first 10 hours o f 
release, after which release is minimal.
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Figure 3-10: Dexamethasone elution from loaded HNTs. Error bars are standard 
deviation, n  =  5.
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This elution from 50 mg o f  HNTs is above the desired micro to nano molar range 
to stimulate differentiation o f  MSCs towards osteoblastic lineage. Dex release from 
scaffolds was also studied for scaffolds with only 5% o f HNTs loaded with Dex (Figure 
3-11). Drug release was slow and concentration o f drug released from scaffolds is much 
lower compared to HNTs. The drug release may be even more extended when scaffold 
degradation exposes more HNTs to extracellular fluids (in vivo).
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Figure 3-11: Dexamethasone release from CPC scaffolds loaded with Dex doped 
HNTs.
Drug release from CPC scaffolds was less than that from HNTs alone. This result 
may be attributed to the surface release and as the scaffolds were not porous, doped 
HNTs in the matrix did not contribute to the release.
3.3.6 Cvtoloeical Assays for Osteoconductive Scaffolds
As the CPC scaffolds were opaque, bright field microscopy or confocal 
microscopy images were not taken. An indirect method was used to estimate ECM. 
Collagen content was estimated from PSR staining, and destaining; acidic
4 0
mucopolysaccharides were estimated from AB staining and destaining. Alkaline 
phosphatase activity was assayed to assure osteoblastic lineage o f  the cells.
3.3.6.1 Picrosirus Red Staining
PSR staining was used to estimate collagen content. Graphical representation o f 
PSR stain absorbance is shown in Figure 3-12. Higher absorbance indicates greater 
collagen content secreted by osteoblasts on the scaffolds.
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Figure 3-12: Picrosirus red staining o f osteoconductive scaffolds. Error bars are 
standard deviation, n  =  6 wells.
On average, more collagen synthesis was observed on Day 14 than on Day 7. 
However, the amounts o f  collagen synthesized among all the groups on a given day o f 
staining were not statistically different. From this collagen synthesis estimation, it is 
inferred that cells are viable and they produce ECM production on the CPC scaffolds.
3.3.6.2 Alcian Blue S ta in im
To estimate synthesis o f  ECM molecules other than collagen, alcian blue staining 
was used to identify acidic mucopolysaccharides. Figure 3-13 is a graphical 
representation o f alcian blue staining for all the scaffolds for two test days.
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Figure 3-13: Alcian blue staining o f  osteoconductive CPC scaffolds. Error bars are 
standard deviation, n =  6 wells.
Higher absorbance indicates higher acidic mucopolysaccharides synthesis. On 
Day 7, acidic mucopolysaccharides synthesis was almost the same across all CPC 
scaffold groups. On Day 14 mucopolysaccharide synthesis improved with an increasing 
concentration o f HNTs. CPC scaffolds with 15% HNTs was stained highest indicating 
higher acidic mucopolysaccharides synthesis.
Staining results from picrosirus red and alcian blue suggest that CPC surfaces are 
conducive for osteogenesis and cell viability. Production o f ECM molecules is a critical 
factor that indicates cell proliferation and tissue regeneration. During bone formation, 
ECM molecules are synthesized and later mineralized to form a compact bone.
3.3.6.3 Alkaline Phosphatase Activity
Osteogenic lineage o f cell lines were assayed using ALPase activity. All the 
groups o f  CPC scaffold had a strong ALPase activity, preserving osteoblastic lineage o f 
cell lines as shown in Figure 3-14. Cells had enhanced ALPase activity on Day 14 
compared to Day 7. Pronounced increase in ALPase activity was seen in CPC without
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HNTs and CPCs with 10% wt. HNTs. Differences among groups on a given day o f  assay 
were not statistically significant.
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Figure 3-14: Alkaline phosphatase activity assay for osteoconductive CPC scaffolds. 
Error bars are standard deviation, n  =  6 wells.
All the histochemical assays indicate that the presence o f HNTs in CPCs is not 
toxic for osteoblasts; instead, scaffolds are conducive for cell attachment and viability. 
These results establish that these CPCs are osteoconductive.
3.3.7 Cvtoloeical Assays for Osteoinductive Scaffolds
Four sets o f scaffolds were prepared to evaluate the osteoinductive property o f 
CPCs. Setting liquid remains the same for all the formulations except for changes in solid 
components.
Group 1: CPC powder without HNTs 
Group 2: CPC powder with 10% wt. HNTs
Group 3: CPC powder with 5% wt. Dex doped HNTs and 5% wt. plain HNTs 
Group 4: CPC powder with 10% wt. Dex doped HNTs
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From the results o f osteoconductive scaffolds, CPCs with 10% wt. HNTs showed 
the highest ALPase activity among groups with HNTs. Hence, CPCs with 10% wt. HNTs 
were chosen for osteoconductive scaffolds. These groups o f scaffolds were tested for cell 
ECM production and ALPase activity. Scaffolds were seeded with bone marrow stromal 
cells that are pluripotent. These cells can differentiate into osteoblasts, adipocytes, or 
chondrocytes, depending on exposure to differentiation agents. These cells were 
hypothesized to differentiate into osteoblasts as Groups 3 and 4 scaffolds were loaded 
with dexamethasone.
An indirect staining and destaining method was used to estimate ECM production 
by BSCs. PSR stain was used to estimate collagen content, and alcian blue stain was used 
to estimate acidic mucopolysaccharides. Scaffolds were stained on Days 1, 3, 7, and 14 to 
observe gradual changes in ECM production and cell differentiation in the presence o f 
Dex. Closer days were chosen for assays to identify the time taken required for Dex to 
promote osteoblastic differentiation.
3.3.7.1 Picrosirus Red Staining
PSR stain was used to evaluate collagen production on all the scaffolds (Figure
3-15); BSCs were viable and produced ECM across all the test groups. Collagen 
production by cells was not statistically different from day to day. Collagen synthesis 
remained almost the same for a given group on all the days except for Group 3 scaffolds.
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Figure 3-15: Picrosirus red staining for osteoinductive scaffold. Error bars are standard 
deviation, n  =  6 wells.
Group 3 scaffolds showed less collagen synthesis on experiment Days 1 and 3. By 
Day 7 and 14, staining o f  these scaffolds was equal to that o f  the other group scaffolds.
By the end o f  Day 14, all the scaffolds were equally stained with PSR stain referring to 
the similar amount o f collagen production by cells on all the scaffolds.
33.1 .2  Alcian Blue Staining
Alcian blue stain was used to estimate acidic mucopolysaccharides produced by 
the BSCs (Figure 3-16). Each group o f scaffolds followed a different trend on each day 
o f the experiment. Staining for Group 1 scaffolds increased for Day 3 and decreased 
slightly on Days 7 and 14. Staining on Group 2 scaffolds had deep staining on Day 7 and 
less staining on the other days. Group 3 scaffolds showed similar staining for all the test 
days. Group 4 scaffolds were deeply stained on Day 14 compared to the other days.
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Figure 3-16: Alcian blue staining for osteoinductive scaffolds. Error bars are standard 
deviation, n  =  6 wells.
Results from picrosirus red and alcian blue stains suggest cytocompatibility o f 
these scaffolds with bone marrow stromal cells. The presence o f  dexamethasone did not 
contribute to enhanced or decreased ECM synthesis.
3.3.7.3 Alkaline Phosphatase Activity Assay
According to the hypothesis, scaffold Groups 3 and 4 would induce differentiation 
o f  BSCs towards an osteoblastic lineage because they contained different concentrations 
o f  Dex-doped ETNTs. Hence, more ALPase activity was predicted in these groups. 
Staining results o f  ALPase assay are shown in Figure 3-17. Differentiation was more 
pronounced on Group 2 scaffolds that contained empty HNTs. Scaffolds o f Groups 3 and 
4, containing Dex-loaded HNTs, did not induce osteoblastic differentiation in the BSCs. 
Cell culture wells containing Group 2 scaffolds were deeply stained in purple while the 
other wells were stained slightly or not at all.
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Figure 3-17: Alkaline phosphatase activity assay for osteoinductive scaffolds. Error 
bars are standard deviation, n  =  6 wells.
ALPase activity on Day 14 was slightly higher for the Group 2 scaffolds than it 
was for the other groups. The inability o f Group 3 and 4 scaffolds to induce 
differentiation may be attributed to higher concentrations o f  Dex release. The optimum 
concentration o f Dex needed to induce osteogenic differentiation is in micro to nano 
moles range [59], and these scaffolds may have eluted Dex beyond this range.
The ability o f  plain HNTs to induce osteogenic differentiation was previously 
reported for differentiation o f stem cells on biopolymers with added nanoclay [64], This 
study and previous studies indicate that HNTs inherently are inducers for osteogenic 
differentiation.
3.4 Conclusions and Future W ork
We conclude that CPCs fabricated using TTCP and DCPA as the solid phase and 
10% chitosan lactate solution as the setting liquid have good osteoconductive nature.
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Osteoconductivity is understood from abundant ECM synthesis by the cells, evident from 
staining results. PSR and Alcian blue staining was used to determine ECM substances, 
collagen and acidic mucopolysaccharides. ALPase activity was assayed to support 
osteoblastic phenotype o f the cells used.
Mechanical properties o f the above formulation can be increased by the addition 
o f HNTs, a type o f  nano particle with a hollow tubular structure. Compressive strength o f 
CPCs increases significantly by adding 5% wt. HNTs to initial CPC.
Surface roughness was increased by the addition o f  HNTs, which favored cell 
attachment, proliferation, and abundant ECM synthesis. FTIR was utilized to analyze the 
composition o f CPCs after setting, and it revealed that the additional HNTs increased HA 
production by acting as seeding agents for precipitation o f HA.
Extended release o f Dex was seen from CPC scaffolds and from HNTs. These 
Dex-loaded HNTs were used in varied proportions in the fabrication o f  osteoinductive 
scaffolds. These osteoinductive scaffolds were seeded with bone marrow stromal cells to 
evaluate osteoinductive nature o f the formulated CPCs. Dex-loaded HNTs in the 
scaffolds induced differentiation in BSCs after 14 days while scaffolds with empty HNTs 
induced differentiation towards osteoblastic lineage after 3 days. At the end o f  the 14th 
day, scaffolds containing non-loaded HNTs had the highest amount o f ALPase activity, 
suggesting maximum differentiation o f BSCs to osteoblastic phenotype [65].
The promotion o f  BSC differentiation to osteoblastic phenotype by HNTs can be 
explored further with different compositions. HNTs loaded with different drugs, 
antibiotics, growth factors and chemotherapeutic agents can be used to fabricate CPCs. 
The addition o f  other polymers can be considered to enhance the mechanical properties
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o f CPCs further, and in vivo experiments can be performed on small animals to evaluate 
the effectiveness o f  the CPCs fabricated.
CHAPTER 4
NOVEL CALCIUM PHOSPHATE CEMENT HYDROGELS
4.1 Introduction
4.1.1 Hydrogels
The term hydrogels refers to a 3-dimensional matrix o f polymer that can hold 
water without dissolving in an aqueous environment. Many hydrophilic polymers can be 
used in the preparation o f hydrogels. Based on their origin, chemical nature, and 
degradability, hydrogels can be classified into many categories. The basic principle 
behind the preparation o f hydrogels is crosslinking o f hydrophilic polymers. Many 
agents, both physical and chemical in nature, can promote crosslinking. Physical 
crosslinking agents currently used are temperature, ultra violet radiation, magnetic field, 
electric field, pressure, and sound. Chemical crosslinking agents may be ionic solvents, 
enzymes, and pH. In general, chemical crosslinking is supposed to be a strong 
crosslinking method that generates strong and mechanically stable hydrogels [66, 67].
Materials used in the preparation o f  hydrogels are diverse in their chemical nature 
and origin. Naturally occurring and commonly used polymers are agarose, gelatin, 
alginate, hyaluronic acid, starch, chitosan, and collagen. Synthetic polymers have been 
researched to improve naturally occurring polymers and tailor them to achieve control 
over various aspects in the fabrication process, including the rate o f crosslinking and 
polymerization. Synthetic polymers used in preparation o f hydrogels are poly(ethylene
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glycol), poly(lactic-o-glycolic) acid, acrylic acid, methacrylate, poly(propylene fumarate, 
polyphosphazenes, and polyanhydrides. Biodegradable polymers are available in both 
naturally occurring and synthetic polymers [7 ,68],
Hydrogels are widely used in biomedical applications because their properties 
mimic in vivo conditions. For biomedical purposes, hydrogels are used in tissue 
engineering, regenerative medicine, cell encapsulation, biosensors, contact lenses, and 
drug delivery systems. Hydrogels have an interesting application in drug delivery as the 
release o f  drug molecules form their matrix can be controlled through pH, ionic strength, 
sensitivity to enzymes, and glucose. They are used in controlled, extended, and sustained 
drug delivery systems. Hydrogels are also used as vehicles for growth factor delivery, 
gene delivery, and cell delivery [7, 67, 69].
Another interesting application o f hydrogels is their use as a coating material for 
orthopedic implants. Improved osteointegration was reported when hydrogel coatings 
with growth factors were used on orthopedic implants. Hydrogels can coat the complex 
geometries o f  implants, and they can be loaded with different biomolecules for various 
purposes [70].
Alginate hydrogels have good cytocompatibility and biodegradability, and they 
can promote cell proliferation. Chemically, they are polysaccharides o f  [1-D-mannuronic 
acid and a-L-guluronic acid extracted from red seaweeds. Alginate is a US FDA 
approved polymer with diverse applications in regenerative medicine and drug delivery. 
Ionic crosslinking using divalent cations is the most common method o f fabrication o f 
alginate hydrogels. Chemical modifications to alginate by incorporating poly (N- 
isopropyl acrylamide) and Pluronic F I27 has enabled the preparation o f
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thermoresponsive hydrogels that undergo gelation at 32-37°C. The photo initiator, 
Irgacure 2959 promotes cross-linking in methacrylate alginate. Alginate in combination 
with other biopolymers such as chitosan, gelatin, and collagen had improved 
biocompatibility and degradation for tissue engineering. Alginate hydrogels have also 
been applied to cartilage and bone regeneration, demonstrating their potential in tissue 
regeneration [71].
Alginate and chitosan hybrid polymers were used to prepare scaffolds for 
cartilage tissue engineering. The scaffolds improved cell proliferation and collagen type 
II production, and they preserved the cell phenotypes o f chondrocytes [72], Other hybrid 
hydrogels with CPCs have produced interesting results. Alginate-CPC scaffolds 
promoted early differentiation o f  bone marrow stromal cells into osteoblastic phenotypes. 
Alginate addition improved mechanical properties o f CPCs [73],
4.1.2 Implant Failure
Even with advances in science and technologies, implant failure is still a 
challenge. Implant failures are caused by aseptic loosening, infections, implant fracture, 
periprosthetic fracture, and arthrofibrosis. Aseptic loosening and infections are the 
leading causes for metal implant failures. Aseptic loosening can be promoted by several 
conditions, including a host immune reaction to metals, wear and tear o f the coating on 
metal surfaces, and osteolysis. Initially, this complication was attribute to the toxic 
effects o f  bone cements, but similar observations were made in uncemented implants.
The mechanism o f aseptic loosening was studied to make the necessary modifications to 
implants and surgical methods. Phagocytosis o f  particulate matter form the wear and tear 
o f implant coatings or cement leads to activation o f  cascade o f  cellular pathways to
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release inflammatory mediators. These inflammatory mediators attack phagocytes and 
activation o f  osteoclasts, which leads to bone resorption around the site o f implantation. 
Effective strategies to prevent implant failure involve prevention o f  osteoclast activation 
and activation o f osteoblast [74],
Surface modification o f  metal to promote cell growth and osseointegration has 
been investigated by many researchers. Coating metal surfaces with hydroxyapatite-like 
compounds, hydrogels, biomolecules, and biophosphonates revealed encouraging results. 
This approach o f  coating metals had significantly reduced the problems with implant 
loosening but there is a scope for improvement in the choice o f biomaterials and the 
methods o f  coating [32],
Postoperative infections are the leading cause for revisions in many surgeries. 
Even though the incidence o f  infections is about 4%, the increased number o f surgeries 
every year result in a significantly large number o f  revisions. Infections due to gram 
positive {Staphylococcus aureus and Staphylococcus epidermidis) and gram negative 
{Escherichia coli and Pseudomonas aeruginosa) are common. Occurrence o f biofilms is 
the most challenging for treatment. After adhesion o f bacteria and pathogens on the 
implant’s surface, an exopolysaccharide layer is developed. Most antibiotic treatments 
are ineffective against biofilms as they require high concentration (about 1000 times the 
regular dose). Preventing bacterial growth within the first 3-4 hours is the key to 
prevention o f bacterial infection and biofilm formation. Antibiotic-releasing polymer 
coatings (both biodegradable and non-degradable), hydroxyapatite coatings, and silver- 
releasing coatings were documented to be effective [75].
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4.1.3 Objective and Rationale
This section o f the research attempts to use a novel hydrogel coating to address 
aseptic loosening and infection. Aseptic loosening o f metal implants is caused by poor 
osseointegration o f the implants with the surrounding bone tissue. Modifying the surface 
o f metals to promote cell growth can result in better osseointegration. At the same time, 
the coating must not promote biofilm formation; instead, it is desired to inhibit microbial 
survival.
The objective o f  this section o f the dissertation is to formulate, fabricate, and 
evaluate novel hydrogel using alginate hydrogel enhanced with HNTs and CPCs. The 
rationale behind using HNT and CPCs is as follows. CPCs are osteoconductive, and the 
results from Chapter 3 support their osteoconductive and osteoinductive nature. HNTs 
can also be loaded with different types o f  antibiotics that can be released over an 
extended period o f time. These antibiotics will form an anti-infective zone that prevents 
biofilm formation. Hence, these hydrogel coatings are hypothesized to promote osteoblast 
growth and prevent microbial growth at the site o f  prosthetic implantation.
4.2 Materials and Methods
Novel hydrogels were fabricated using TTCP (CaP Biomaterials, East Troy, WI), 
DCPA, sodium alginate, chitosan lactate, HNTs, and calcium chloride (Sigma-Aldrich,
St. Louis, MO) solution as crosslinking agents. Different combinations o f  these chemicals 
were formulated and fabricated. TTCP and DCPA were used in equimolar ratio and will 
be termed as CPC powder from this point onwards. Sterile, autoclaved water was used in 
the preparation o f  all solutions.
54
4.2.1 Hydrogel Preparation
A reverse crosslinking principle was used to fabricatie alginate hydrogels. Sodium 
alginate solution o f  2% w/v was added to a solution o f  1% w/v calcium chloride. To 
sodium alginate solution, HNTs, CPC powder, and chitosan lactate were added to prepare 
the novel hydrogels.
Three novel groups o f alginate hydrogels were prepared in the form o f thin films 
to estimate cytocompatibility. Table 4-1 summarizes different hydrogels’ components 
used to prepare hydrogel films for cytocompatibility assays.
Table 4-1: Components used in the preparation o f hydrogel films for cytocompatibility 
assays.
C o m p o n e n t s ' ^
Group
Sodium
alginate
solution
CPC
powder
Chitosan
lactate
HNTs
Group 1 3 mL 1 g “ -
Group 2 6 mL 1 g 20 mg -
Group 3 6 mL l g 20 mg 60 mg
All the powders required to prepare each group were added to sodium alginate 
solution and mixed using glass mortar and pestle. This mixture was then poured onto 
glass plates to form thin films. Calcium chloride solution was carefully added drop by 
drop to form films o f alginate hydrogels and left for 15 minutes to allow complete 
crosslinking. These hydrogels were placed in 24 well plates and seeded with pre­
osteoblast cells.
To test the antibiotic activity o f  hydrogels, HNTs were loaded with gentamicin 
sulfate. These doped HNTs were used to fabricate hydrogel beads. Three test group
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hydrogel beads were prepared and tested for bacterial inhibition. The composition each 
group is summarized in Table 4-2.
Table 4-2: Components used in the preparation o f hydrogels for antibiotic activity.
C o m p o n e n ts /^  
^/""^  Group
Sodium
alginate
solution
CPC powder Chitosan
lactate
Doped HNTs
Group 1 3 mL - - 30 mg
Group 2 6 mL U - 60 mg
Group 3 6 mL l g 20 mg 60 mg
All the required components for each group were mixed in mortar pestle and the 
mixture was loaded into the syringe. The mixture was added dropwise from an 18 G 
needle into a beaker containing 1% w/v calcium chloride solution, as shown in Figure
4-1. Hydrogel beads were formed instantaneously upon contact with calcium chloride 
solution. Hydrogel beads were left in calcium chloride for 15 minutes to ensure complete 
crosslinking. Beads were then moved into sterile water to maintain hydrated conditions.
Alginate mixture
Calcium chloride solution 
Figure 4-1: Illustration showing alginate beads preparation.
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4.2.2 HNT Loading
HNTs were vacuum loaded with gentamicin sulfate. Gentamicin sulfate solution 
was prepared at a concentration o f  50 mg/mL in sterile autoclaved water. To this solution, 
HNTs were added and sonicated in waterbath for 30 minutes. The sonication promotes 
uniform dispersion o f  HNTs and breaks down any agglomeration present. After 
sonication, contents were placed in a vacuum chamber for 2 hours. After four cycles o f 
sonication and vacuuming, the mixture was left in the vacuum chamber for 12 hours. The 
mixture was centrifuged to separate HNTs from the supernatant. HNTs were washed with 
distilled water and vacuum dried.
The HNTs thus obtained were doped with gentamicin sulfate. These doped HNTs 
were used to prepare alginate hydrogels and were tested for antibiotic activity.
4.2.3 Cell Culture and Staining
Mouse preosteoblast cell lines MC3T3 -E l (ATCC® CRL-2593™) were cultured 
on the novel hydrogels to test the cytocompatibility. These cells are committed to 
osteoblastic lineage. Upon exposure to differentiating agents like ascorbic acid or BMPs, 
these cells differentiate into osteoblasts. Cytocompatibility was estimated on hydrogel 
films prepared by measuring ECM production. These cells play an important role in the 
synthesis o f  ECM molecules like collagen and mucopolysaccharides. Good cell 
proliferation and viability correspond to more ECM production.
These preosteoblast cells were seeded onto the three groups o f  hydrogel films 
prepared. ECM production was estimated by measuring collagen and acidic 
mucopolysaccharides. PR stain was used to visualize collagen content and AB stain for 
acidic mucopolysaccharides.
57
On Days 3, 7 and 14 after seeding the cells, hydrogel films were fixed using 95% 
ethanol solution. These fixed hydrogel films with cells were stained with PR and AB to 
estimate ECM production. Staining protocols for each stain were followed as described 
earlier. As the hydrogel films were opaque, light microscopy for imaging was not 
possible. Indirect estimation was done using destaining method. Glacial acetic acid 7% 
solution was used as destaining solution. After staining the hydrogel films, destaining 
solution was added to remove the dye that was fixed on the films. Destaining solution 
was then collected and measured for concentration o f  staining dye using UV 
spectrophotometry.
4.2.4 Scanning Electron Microscopy
The prepared hydrogel beads were lyophilized, and surface topography was 
observed using scanning electron microscopy. For lyophilization, hydrogel beads were 
frozen at — 20°C for 12 hours. These frozen hydrogel beads were attached to lyophilizer 
for 36 hours for freeze drying.
Lyophilized hydrogels were used for SEM imaging as they retained the delicate 
alginate matrix without collapsing. In freeze drying, water is removed by sublimation 
process. Solid water is vaporized and removed without heating and without collapsing the 
matrix.
4.2.5 Drug Elution
Release o f  gentamicin sulfate from hydrogel beads with doped HNTs was studied 
in simulated biological fluid. Three groups containing gentamicin-loaded HNTs were 
used for this study. Specimens were placed in 2 mL tubes and 1 mL o f  simulated 
biological fluid was added. All the tubes were placed on a rocking apparatus to ensure
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constant movement o f the beads to account equally for drug release from whole o f  the 
bead’s surface. At regular intervals, solution from the tubes was replaced with fresh SBF. 
Collected solution was stored at 4°C and later quantified for gentamicin content.
As UV-Vis spectrophotometry cannot directly quantify gentamicin sulfate, an 
indirect method was employed. Equal volumes o f the test sample containing gentamicin 
sulfate were added to isopropyl alcohol and OPTA reagent. This mixture was allowed to 
react for 30 minutes at room temperature, and absorbance was measured at 331 nm. 
OPTA regent was prepared by mixing 2.5 g o f  o-phthaldialdehyde, 62.5 mL methanol, 3 
mL P-mercaptopethanol, and 560 mL o f 0.04 sodium borate. This reagent was used after 
24 hours o f incubation at room temperature.
4.2.6 Antibiotic Activity
To measure bactericidal property o f  gentamicin, hydrogel beads were placed in 
cultures o f gram negative bacteria, Escherichia coli. E. coli o f  DH5a strain were cultured 
in Luria broth (LB) and plated on LB agar plates at 37°C. A single colony was taken from 
this culture, suspended in saline solution, and diluted the suspension to 0.5 McFarland 
standard; 50 pL o f bacterial suspension was uniformly spread over fresh Mueller-Hinton 
agar plate (Fisher Scientific, Swedesboro, NJ). Test beads and control discs were placed 
over these plates and incubated for 18 hours at 37°C. Zones o f  inhibition were measured 
using digital Vernier calipers. Figure 4-2 illustrates the process for the antibacterial 
studies. A Mueller-Hinton agar plate containing no hydrogel beads was used as a 
negative control, and a standard gentamicin disc (60 jig) was used as a positive control.
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Figure 4-2: Bacterial test process. 1) One colony o f E. coli is picked from LB agar 
plate. 2) The bacterial suspension is diluted to 0.5 McFarland standard. 3) 50 pL o f 
bacterial suspension is pipetted out. 4) The hydrogel bead is placed on the Muller- 
Hinton agar plate, leading to a zone o f  inhibition.
4.3 Results and Discussion
4.3.1 Surface Topographical Analysis
Simple observation o f different groups o f  hydrogels reveal the effect o f 
the additives. Alginate-only hydrogels were translucent appearing like clear glass 
beads. The presence o f HNTs and uniform distribution o f  these nanoparticles 
rendered alginate hydrogels opaque. As seen in Figure 4-3, the addition o f HNTs 
reduced transparency o f  the hydrogels. Hydrogels with CPC powders were 
opaque and white in color. The addition o f  chitosan lactate to alginate hydrogels 
along with CPC powder had a similar effect on their physical properties.
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Figure 4-3: Photograph o f  hydrogel beads. A) Alginate hydrogel. B) Alginate hydrogel 
added with HNTs. C) Alginate hydrogel added with CPC powders and HNTs.
D) Alginate hydrogel added with CPC powders, chitosan lactate and HNTs.
Images o f lyophilized hydrogel beads were taken at 50x , lOOOx, and 2000x 
magnifications to observe changes in surface morphologies. Differences in surface 
roughness were evident even at lower concentration. Group 1 hydrogel beads had only 
HNTs, Group 2 beads contain HNTs and CPC powders, Group 3 had CPC powders, 
HNTs and chitosan lactate. The surface o f Group 1, when observed at 50x  magnification 
on the SEM image (Figure 4-4), appears smooth without visible roughness. Patterned 
roughness in the form o f ridges was observed in Group 2 hydrogel beads, even at lower 
magnification. The addition o f  CPC powders greatly increased surface roughness o f  the 
hydrogel beads. Similarly, the roughness o f  the hydrogel’s surface topography was much 
rougher in Group 3 than in Group 1.
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Group 1 Group 2 Group 3
Figure 4-4: Hydrogel beads at 50x  magnification [76].
At a higher magnification o f  lOOOx, surfaces reveal more roughness in Groups 2 
and 3 (Figure 4-5). The increased roughness is expected with the addition o f  CPC 
powder. In Group 1, the added HNTs introduced a texture suggesting slight roughness, 
but roughness was small compared to Groups 2 and 3. The surface topologies o f Groups 
1 and 2 hydrogels were drastic. Particles o f CPC powder were well integrated into the 
Group 2 alginate matrix, contributing to increased roughness. Surface topographies o f 
Groups 2 and 3 hydrogels were similar as their roughness was primarily caused by the 
addition o f CPC powders. The presence o f  chitosan lactate in Group 3 hydrogels is 
evident from a change in surface appearance when compared to Group 2. Group 3 
hydrogels appear to have a subtle sheath covering particles o f  CPC powders, giving them 
a smoother surface than Group 2 hydrogel beads.
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Group 1 Group 2 Group 3
Figure 4-5: Hydrogel beads at lOOOx magnification.
As seen in Figure 4-6, at a higher magnification o f 2000x, surface features are 
more pronounced. The Group 1 hydrogel surface remains mostly smooth, except for the 
presence o f  a few micron sized particles, probably clusters o f alginate or HNTs or both. 
The Group 2 surface on the other hand shows irregularly shaped large particles o f  CPC 
powders in matrix o f  alginate. Similar observation was made from Group 3 SEM images
Group 1 Group 2 Group 3
Figure 4-6: Hydrogel beads at 2000x magnification.
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4.3.2 Cytocompatibilitv
Pre-osteoblast cells were used to estimate the cellular response to the novel 
hydrogels. Cells were seeded onto hydrogel films that were prepared according to the 
composition mentioned in Table 4-1, and cellular response was evaluated for a period o f 
14 days. Indirect estimation o f collagen and mucopolysaccharide produced by these cells 
was measured on Days 3, 7 and 14. The following hydrogel film compositions were used. 
Group 1: Alginate and CPC powder 
Group 2: Alginate, CPC powder and chitosan lactate 
Group 3: Alginate, CPC powder, chitosan lactate and HNTs 
Figure 4-7 is a graph o f  the absorbance o f  picrosirus red stain eluted in 7% 
glacial acetic acid from fixed cell culture samples for different hydrogel films, measured 
at 353 nm. Readings were taken for 6 wells and the average was plotted. Error bars 
represent the standard error calculated for the samples. The absorbance value is directly 
proportional to the amount o f collagen synthesized by the cells on respective hydrogel 
films.
On Day 3, collagen synthesis was lowest on hydrogel film Group 1 containing 
alginate and CPC powders. Group 3 hydrogel films promoted synthesis o f  collagen. An 
almost equal amount o f collagen synthesis was observed in all groups o f  hydrogel films 
by Day 7. Results from Day 14 suggest that hydrogel films from Group 2 had the highest 
amount o f  collagen synthesis among the test groups. Hydrogel films from Group 2 had a 
specific trend o f  increasing collagen synthesis over this 14 Day experiment. Group 3 
hydrogel films containing HNTs showed the highest collagen synthesis for Days 3 and 7.
6 4
We infer that HNTs promote initial adhesion and proliferation o f  pre-osteoblasts and thus 
promote early ECM production on the hydrogel films.
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Figure 4-7: Picrosirus red staining o f pre-osteoblast cells on hydrogel films for Days 3, 
7, and 14. Error bars are standard error o f mean, n  =  6 wells.
After the regular staining protocol for alcian blue on the hydrogel films, 
destaining was done using 7% glacial acetic acid. This solution containing alcian blue 
stain was quantified by UV-Vis spectrophotometry at 604 nm. Figure 4-8 is a graph 
plotted against absorbance o f alcian blue stain vs days o f  experiment. An average o f  6 
wells readings were taken to plot the graph with error bars representing standard error.
Group 1 hydrogel films show the highest amount o f  alcian blue stain on Day 3, 
meaning cells on Group 1 films containing CPC powder and alginate synthesized the 
highest amount o f  mucopolysaccharides compared to the other groups. The least amount 
o f  mucopolysaccharide synthesis was observed on Group 3 hydrogel films containing 
CPC powder, chitosan lactate and HNTs. On Days 7 and 14, Group 2 hydrogel films 
synthesized the highest amount o f mucopolysaccharides. A declining trend o f
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mucopolysaccharide synthesis was observed on Group 1 hydrogel films over the 14 day 
experiment. On the other hand, Group 2 hydrogel films maintained the same amount o f 
mucopolysaccharide synthesis throughout the 2 week experiment. Group 2 hydrogel 
films had the highest mucopolysaccharide synthesized on Day 3, declined on Day 7 and 
maintained the same level on Day 14.
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Figure 4-8: Graph o f alcian blue staining o f  pre-osteoblast cells on hydrogel films for 
Days 3, 7, and 14. Error bars are standard error o f mean, n  =  6 wells.
A stacked graph o f picrosirus red and alcian blue stains are shown in Figure 4-9. 
Considering collagen and mucopolysaccharides as primary components o f  ECM, it is 
inferred that ECM production by pre-osteoblasts is highest on Day 3 on Group 3 hydrogel 
films containing CPC powder, chitosan lactate and HNTs. For Days 7 and 14, Group 2 
hydrogel films show maximum ECM production. Group 1 hydrogel films showed the 
least ECM synthesis on all 3 Days o f experiments.
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Figure 4-9: Total ECM synthesized by pre-osteoblasts on different hydrogel films. 
Darker part in each group o f the bar represents collagen and the lighter part o f the bar 
represents mucopolysaccharide amount.
These cytocompatibility studies indicate that pre-osteoblasts respond to hydrogels 
in different patterns. Cells are able to adhere, proliferate, and synthesize ECM molecules 
on these hydrogel films. This result shows that the novel hydrogel films are 
osteoconductive and promote ECM production.
4.3.3 Drug Release
Gentamicin release from different hydrogel beads was quantified and compared 
with minimum effective concentration for bactericidal effects. To ensure reproducibility 
o f the data, elution studies were done in multiples o f  6. Average absorbance was plotted 
against time in hours, as shown in Figure 4-10. Standard error was calculated and is 
represented as error bars. Similar results o f  extended release o f GS from CPCs is 
available in the literature [62].
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Figure 4-10: Gentamicin sulfate release from hydrogel beads. Group 1 hydrogel beads 
contain sodium alginate and doped HNTs. Group 2 hydrogel beads contain sodium 
alginate, CPC powder and doped HNTs. Group 3 hydrogel beads contain sodium 
alginate, CPC powder, chitosan lactate and doped HNTs. Dotted line on the bottom o f 
graph is the minimum effective concentration o f gentamicin (15 pg/mL). Error bars are 
standard deviation, n  =  6.
The effective concentration o f  gentamicin to show its bactericidal action is 15 
pg/mL represented by a dotted line in the graph. All the hydrogel beads elute beyond this 
concentration. To reach this effective dose concentration, it takes less than 10 minutes for 
all the hydrogel beads. The first 6 hours after surgery are important because bacterial 
cells adhere and colonize the implant surface and may result in biofilm formation only 
during this period. In the first 6 hours. Group 1 and Group 3 hydrogels were able to elute 
gentamicin in six times the effective concentration. Group 2 hydrogel beads were able to 
release three times the required concentration in the first 6 hours.
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All the hydrogel beads loaded with doped HNTs follow a similar release trend o f 
initial burst release followed by low and extended release o f  gentamicin for two days. 
Release data beyond two days was not quantified as the hydrogel beads lost their 
structure due to a constant rocking movement. This drug release data suggests that 
hydrogels can release gentamicin at levels higher than the effective dose and extends 
release up to 48 hours.
4.3.4 Antibiotic Activity
From the drug elution studies, hydrogel beads with doped HNTs were able to 
release gentamicin at desired concentrations. These hydrogel beads were tested in 
cultures o f  E. coli bacteria, and the results are discussed in this section. All the groups 
were tested in multiples o f three in six trials.
Control groups for this testing are shown in Figure 4-11, Panel A shows a 
negative control plate containing no bacteria to show that there was no contamination o f 
bacteria. Panel B shows a positive control containing a lawn o f E. coli bacteria without 
any samples to show that the Mueller-Hinton agar plates themselves are not showing any 
antibiotic properties. Panel C shows a second positive control in which a paper disc 
containing 60 pg  o f  gentamicin was placed in bacteria cultured plate, leading to a clean 
zone o f  inhibition without any bacterial growth. The zone o f  inhibition was measured to 
be 3 ± 0.2 cm.
69
A B
y
c
Figure 4-11: Control groups for antibiotic susceptibility tests. A) Negative control 
plate containing no bacteria. B) Positive control plate containing only E. coli.
C) Positive control plate containing gentamicin control disc in E. coli showing zone o f 
inhibition.
Figure 4-12 shows the control groups containing HNTs that were not doped with 
gentamicin. Three hydrogel beads were placed as a group in each quadrant o f Mueller- 
Hinton agar plates and incubated for 18 hours. Four quadrants o f the plate were 
delineated with four hydrogel groups. Quadrant A contains control alginate hydrogel 
groups without HNTs. Quadrant B contains sodium alginate and HNTs. Quadrant C 
contains sodium alginate, CPC powder and HNTs. Quadrant D contains sodium alginate, 
CPC powder, chitosan lactate and HNTs. HNTs used for all these groups were not doped 
with gentamicin. The bacterial growth was not inhibited by the control hydrogel groups, 
indicating that none o f  the constituents o f the hydrogel beads including sodium alginate, 
CPC powder, chitosan lactate, and HNTs inherently have antibiotic activity against E. 
coli bacteria.
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Figure 4-12: Control groups o f hydrogel beads. The petri plate was marked into 4 
quadrants for each hydrogel group. Quadrant A contains control alginate hydrogel 
groups without HNTs. Quadrant B contains sodium alginate and HNTs. Quadrant C 
contains sodium alginate, CPC powder and HNTs. Quadrant D contains sodium 
alginate, CPC powder, chitosan lactate, and HNTs. HNTs used for all these groups 
were not doped with gentamicin.
All the hydrogel groups prepared using HNTs doped with gentamicin were able to 
show a clear zone o f  inhibition in bacterial culture plates, as seen in Figure 4-13. The 
zones o f  inhibition were measured for each group. The average for hydrogel beads 
containing sodium alginate and HNTs was 2.95 ± 0.07 cm. The average for hydrogel 
beads containing sodium alginate, CPC powder, and HNTs was 3.22 ± 0.03 cm. The 
average for hydrogel beads containing sodium alginate, CPC powder, chitosan lactate, 
and HNTs was 3.06 ± 0.03 cm. These tests show that these hydrogels can prevent
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bacterial growth and provide an effective anti-infective zone. The zones o f inhibition for 
hydrogel groups are larger than those o f the control disc containing 60 pg o f  gentamicin.
n
c
Figure 4-13: Alginate hydrogels with doped HNTs in E. coli bacterial cultures. 
Hydrogels in picture A contain sodium alginate and doped HNTs. The upper half o f  the 
second plate denoted by B contains sodium alginate, CPC powder and doped HNTs. C 
contains hydrogels with sodium alginate, CPC powder, chitosan lactate, and doped 
HNTs.
4.4 Conclusions and Future Work
Novel hydrogels were prepared using alginate and CPCs. These hydrogels were 
enhanced with chitosan and HNTs. Improved surface roughness in these hydrogels was 
demonstrated using SEM images. These hydrogels were prepared in the form o f beads 
and films. The novel hydrogel films were tested for cytocompatibility using osteoblast 
cell lines.
HNTs doped with gentamicin were added to hydrogels to improve their antibiotic 
activity. Extended release from these hydrogels was demonstrated and tested for 
antibiotic activity. Drug elution was recorded for 48 hours. Antibiotic susceptibility tests
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were performed using agar diffusion methods. Antibiotic activity o f  these hydrogels was 
demonstrated against E. coli bacteria [77],
Future work may use HNTs doped with growth factors to create novel hydrogels. 
Composite hydrogels can be fabricated from a combination o f doped HNTs containing 
angiogenic and bone morphogenetic proteins. Coating o f  these hydrogels on titanium 
implants can be tested in vivo in an animal model.
CHAPTER 5
3D PRINTING PATIENT SPECIFIC GRAFTS AND IMPLANTS
5.1 Introduction
5.1.1 3D Printing
Commonly referred to as rapid prototyping, fabrication o f  unique 3D objects can 
be achieved by subtractive or additive processing. In subtractive manufacturing, materials 
are removed to create the final object. Lasers, routers, mills, and water jets are used in 
this method. Disadvantages with subtractive manufacturing are material waste and 
difficulty in working with complex geometrical objects. The opposite method o f 
fabricating 3D objects is by adding materials in layer by layer fashion. This method is 
also known as additive manufacturing or 3D printing. Additive manufacturing can use 
many technologies such as fused deposition modeling, stereolithography, selective laser 
sintering, laminated object manufacturing, solid ground curing, laser metal deposition, 
laser engineered net shaping, ink-jet printing, infrared, and masking systems [78].
All the additive manufacturing technologies start with a CAD file. CAD files are 
exported as STL files because o f its compatibility across different software. STL files are 
sliced into two-dimensional layers and stacked one above the other to build the 3D 
object. After the data are sliced and coded, they are passed through the 3D printer to 
finish the job. After the object is printed, it may be further processed to have a desired 
surface texture.
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These steps are illustrated in Figure 5-1 as an example. In the first step, a mug is 
modelled in a CAD program. In the second step, it is converted to an STL file. In this 
example, the object is printed on a MakerBot® 3D printer. Hence, the STL file is 
processed by a program specified by the manufacturer. In the last step, the object is 
printed in a plastic polymer, in this case, polylactic acid (PLA).
A B C C
Figure 5-1: Steps involved in conventional 3D printing. A) Creating a digital 3D 
model with CAD program. B) Saving the digital file in STL format. C) Processing and 
setting parameters on MakerBot Desktop® software. D) 3D object printed in a PLA 
polymer.
This research used fused deposition modeling technology to fabricate 3D objects. 
In this method, thermoplastic polymers in the form o f thin filaments are used by the 3D 
printers to create the object. Many 3D printers based on this technology are commercially 
available, with wide flexibility in the types o f  thermoplastics used.
CAD programs like Solidworks, Blender, and FreeCAD can be used to design and 
edit 3D models according to the required dimensions and parameters. CAD files can also 
be generated by scanning objects in 3D. Digital 3D scanners commercially available can 
be used to convert the real life objects into digital 3D files. The resolution o f  these 3D 
scanners can vary from as low as few microns to centimeters. All these digital files need 
to be converted to a file format that is accepted by the 3D printer software. Most o f  the 
3D printer programs accept STL files. The STL file extension is an acronym for
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stereo lithography, but it has other backronyms, such as “standard triangulation 
language.”
The CAD file in the required format must then be processed by the software 
programs to produce instructions are specific for a 3D printer. These programs are 
supplied with the 3D printer and enable users to adjust various parameters that attribute to 
the quality o f the printed object. Important parameters that can be adjusted are print 
speed, print temperature, resolution along the z  axis, infill percent, and feed rate. These 
input parameters are coded by the program, and instructions are sent to the printer.
After the object is 3D printed, it can be further processed to improve its 
appearance and/or other physical properties. Processes include the removal o f  rafts and 
support, and curing the materials with chemicals.
5.1.2 3D Printing for Biomedical Applications
Additive manufacturing is being explored and researched to broaden its 
applications in various fields including biomedical and medical sectors. The advantages 
o f  3D printing are its cost efficiency, reliability, reproducibility, and customizability. 
Custom prosthetics, implants, fixtures, and surgical tools are fabricated using 3D 
printing. In the field o f  biomedical engineering, scaffolds o f  different geometry, pattern 
and complexity were 3D printed, providing significant contribution to tissue engineering 
[79].
Customized dental and orthopedic implants were 3D printed. Many orthopedic 
implants for spinal, cranial and maxillofacial surgeries were made with titanium and 
other ceramics. The success o f surgeries that use patient-specific implants is high. Skull 
implants made from polyetherketoneketone received FDA approval and have been
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successfully implanted [80], Splints made o f PCL were implanted in infants with 
tracheobronchomalacia, saving the infants from life threatening conditions [81J. Hearing 
aids specific to patients are used in almost all the cases, and this is possible because o f  3D 
printing. Anatomical models made from MRI or CT patient data were used in many 
cases, helping the surgeon to prepare for the surgery with increased success rate o f 
surgeries [82]. Implants 3D printed with chemotherapeutics and antibiotics in a 
biodegradable matrix were studied with promising results [83, 84],
Three-dimensional printing scaffolds for tissue engineering have been studied 
widely. Fused deposition modeling or inkjet printing methods were used to create 
scaffolds with various sizes, shapes, and geometries. Biomaterials including PCL, PLA, 
polylactic glycolic acid (PLGA), HA, and TCP were used for 3D printing. These 
scaffolds were targeted for use in bone and cartilage tissue engineering. The goals of 
these approaches are to provide tissues grafts for critical sized defects. Limitations 
prevent the implantation o f these engineered in vitro cultured tissues as grafts. All the 
tissues are aneurotic, avascular, and alymphatic. Mass transport o f  nutrients and oxygen 
is through diffusion alone, causing hypoxic and undernourishment to the cells in the core 
[11, 85, 86]. Vascularization is one o f challenges faced in printing an organ, and 
proposed solutions to this challenge were to seed either the organ with endothelial cells 
during printing or to include growth factors to induce angiogenesis [87],
5.1.3 Calcaneal Fractures and Current Treatment Strategies
The calcaneus is also called the heel bone, and is present in the foot. It is the 
largest tarsal bone in the foot and has a complex geometry with articulations in three 
axes. The calcaneus articulates with cuboid bone at the calcaneocuboid joint. Articulation
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with talus bone occurs at three facets: anterior subtalar joint, middle subtalar joint, and 
posterior subtalar joint: F igure 5-2 and F igure 5-3.
Anterior talar articulating facet
Middle talar articulating facet 
Posterior talar articulating facet
F igure 5-2: Dorsal view o f calcaneus bone showing different articulating surfaces.
Anterior talus articulating facet 
Middle talus articulating facet
Posterior talus articulating facet 
Cuboid articulating facet
F igure 5-3: Lateral view o f calcaneus bone.
Calcaneal fractures contribute to about 2% o f all fractures reported in emergency 
departments. Diagnosis o f  fractures are done mostly using CT scans by assessing the 
calcaneal height and relations between various joint facets. Fractures o f  the calcaneus are 
classified as intra-articular or extra-articular. The most common cause for intra-articular 
fractures are increased load or compression on the heel. Other causes are trauma or 
accidents. Commonly encountered fractures occur between the middle and anterior 
articulating facets [88],
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The primary goal o f  treating calcaneal fractures is to restore the three-dimensional 
structural anatomy o f the bone. If the articular surfaces are displaced by more than 2 mm, 
then arthritis results from an overload o f the surrounding cartilage. Non-operative, 
operative and open reduction internal fixation (ORIF) are the three approaches used in 
the treatment o f these fractures. Non-operative treatment is practiced in the case o f  extra- 
articular fractures and consists o f  rest, analgesia and supports. In cases o f  intra-articular 
fractures when other approaches fail, ORIF is advised and has been documented to have 
better results. In these surgical approaches, screws, plates, and bone grafts are used for 
restoration o f calcaneal anatomy and structure. For fractures containing malunion, 
arthodesis is performed as a revision surgery to fuse the bones and re-establish their 
alignment. Even with advances in technology and surgical methods, patient morbidity is 
considerable [89]. About 40-85% o f the patients return to work within nine months, while 
20% o f the patients can return to work after a year o f  bed rest [88], Economically viable 
methods to fabricate patient specific grafts can be developed using 3D printing.
5.1.4 Objective and Rationale
The objective o f  this chapter are as follows:
1. To model a bone from CT scan, and 3-Dimensional (3D) print with 
biodegradable biomaterial.
2. To compare similarities and differences in surface geometry o f  contralateral 
bones.
3. To measure the accuracy o f  commercially available, relatively inexpensive 
desktop 3D printers.
4. To 3D print antibiotic-loaded CPCs.
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The rationale behind this research is the bilateral symmetry o f the human skeletal 
system. In ideal conditions, the human body shows bilateral symmetry; however, as the 
human body ages, depending on stress, wear and tear, asymmetrical growth o f bones is 
common. In view o f extreme cases o f  trauma, accident, congenital defects, or cancer 
resection, mirror-imaged grafts can serve as a template and can be modified to meet 
specific requirements. As these grafts are biodegradable, grafts can be seeded with cells 
and cultured in vitro or can be placed in vivo without cell seeding.
5.2 Materials and Methods
5.2.1 Processing Medical Data
Uninjured ankles o f a patient were scanned, and the CT scans were obtained. The 
digital imaging and communications in medicine (DICOM) files were processed using 
3DSlicer software Version 4.5. This freeware allows the users to process CT scans and 
MRI data. After importing the CT scan data into 3DSlicer, the volume-rendering module 
was used to visualize the scans in 3D. Using different presets, various tissues can be 
visualized and optimized using the “shift” to adjust the threshold for a preset. In this case, 
“CT bone” preset was chosen and the CT scan data was represented as seen in Figure 
5-4. This module helps in cropping the CT scan data according to the region o f interest, 
and later can be processed as needed. After cropping the data to show only the right foot 
containing the calcaneal region, the “Crop” module was used to crop the region. As seen 
in Figure 5-5, the cropped data isolated the region o f interest. This isolation allows the 
users to edit the CT scan data with more focus.
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Figure 5-4: Screenshot o f  3DSlicer software in volume rendering module. The left 
column has the option to choose different presets to visualize different tissues. The 
middle panel gives the 3D rendered model o f the CT data. Right pane consists o f  axial, 
sagittal and coronal plane views o f  the CT scan data.
Figure 5-5: 3DSlicer view after processed by cropping module.
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The regions containing right and left calcanei were cropped separately and 
segmented using “editor” module. This editor module enables users to segment, and 
separate different tissues and regions. Tools in this module including paint effect, 
threshold effect and erase label were used, and segmentation o f calcaneus bone was done 
by going through every slice o f CT scan. The resulting model was then saved as mesh for 
further analysis and 3D printing (Figure 5-6).
Figure 5-6: Segmentation o f  calcaneus bone using editor module in 3DSlicer.
5.2.2 Working with CAD Modelled Bones
The segmented right and left calcanei were imported into Blender software 
Version 2.76. Blender is a freeware used for modeling and animation. This software was 
used to clean up the extracted calcanei and produce contralateral calcaneus. The left 
calcaneus was imported, and the mirror option under the object menu was used to create
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contralateral calcaneus bone. Mirroring was done along the x  axis, which corresponds to 
the axial axis. This mirrored left calcaneus was compared with right calcaneus bone for 
similarities and differences. Similarly, the right calcaneus was mirrored and compared 
with the left calcaneus as seen in Figure 5-7. After the bones were prepared for 
corresponding calcanei, the models were exported as meshes in STL format.
Figure 5-7: A) Right calcaneus bone segmented from 3DSlicer. B) Mirrored right 
calcaneus bone appearing similar to left calcaneus.
5.2.3 3D Printing
The original right calcaneus was 3D printed using MakerBot Replicator 5th 
generation, with PLA (Push Plastic, Springdale, AR) filament at following settings with 
raft and supports. Important print settings are temperature at 215°C, print speed at 30 
mm/s, infill at 50%, and layer height at 0.2 mm. Figure 5-8 is the screenshot o f  the 
MakerBot software showing the calcaneus alignment, positioning and print settings.
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Figure 5-8: Screenshot o f  MakerBot software showing print settings and the calcaneus 
bone in the background.
5.2.4 Scanning and Comparing
The MakerBot digitizer was used to scan the printed calcaneus bone in 3D, under 
default settings. To improve the visibility for the scanner, the 3D printed calcaneus was 
spray-coated in white acrylic paint. The scanner and the printed bone were placed in a 
light soft box for better light control. The scanned object was saved in STL format for 
further analysis.
The original and mirrored calcanei were imported into 3DReshaper MRI software 
for geometrical analysis. The first step is to import the STL files o f the bones' models that 
are to be compared. After importing, the files appear under “Mesh groups” on the left 
pane. After selecting the two meshes, they are aligned for geometrical analysis. Under the 
“Move-Align” tab, the “Best Fit Registration” option was chosen to align both meshes 
automatically. After aligning, both the meshes overlap each other. Geometrical 
similarities are measured using the “Measure” tab and selecting “Compare/Inspect.”
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Options are given to choose the reference object, inspection method (2D or 3D), and 
points to be considered. Upon clicking “OK”, another pane appears to choose levels for 
coloration and define upper and lower limits for color representation. Options are given 
for displaying the legend in the scene.
Geometrical deviation was measured across the following groups:
1. CAD modelled right calcaneus and 3D printed calcaneus using Makerbot 5th 
generation printer with PLA
2. Original right calcaneus and mirror imaged contralateral left calcaneus
3. Original left calcaneus and mirror imaged contralateral right calcaneus
5.2.5 3D Printing Antibiotics Loaded CPCs
The CPC formulation mentioned in Chapter 4 was used to 3D print bone cement 
scaffolds on a Hyrel System 30M 3D Printer (Atlanta, GA). This printer has different 
print heads for 3D printing thermoplastics, solutions, and suspensions. The “EMO 25” 
print head supplied by the manufacturer was used to 3D print CPCs. This printer head is a 
motor-driven system with an anodized aluminum body. It can be loaded with viscous 
liquids or clay-like materials that are extruded as the motor pushes the piston (shown in 
Figure 5-9). The nozzle can be changed to luer tip so as to fit needles o f  desired gauges.
Dog bone shaped specimens (70 mm long, 10 mm wide, and 4 mm thick), bars 
(70 mm long, 10 mm wide, and 4 mm thick) and discs (o f 6 mm diameter and 2 mm 
thickness) were modeled in FreeCAD software Version 0.15. All these constructs were 
3D printed.
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Figure 5-9: EMO 25 printer head used for 3D printing CPCs.
This tube was loaded with CPC paste prepared and attached to the 3D printer. 
Repetrel is the software used by this 3D printer to process the STL files. After the file to 
be 3D printed is opened, the left o f  the screen contains the tabs for 3D view, Control, 
Pictures, and Web browser. To the right o f  the screen, options for position o f the object 
and slicing can be accessed, as seen in Figure 5-10.
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Figure  5-10: Repetrel software interface.
Important parameters used for 3D printing bone cements are printing speed 10 
mm/s, layer height o f  0.2 mm, and nozzle diameter o f  1 mm.
CPC added with 1% wt. GS was 3D printed using the above mentioned printing 
parameters and tested for antibiotic activity against E. coli and S. aureus. CPC 
composition was the same with equimolar mixture o f TTCP and DCPA with 10% w/v o f 
chitosan lactate solution. GS was added to the solid phase before the addition o f liquid 
phase o f  bone cement. The solid and liquid phases were mixed in mortar and pestle, and 
the paste was loaded into the EMO tube. Discs o f 6 mm in diameter and 1 mm thickness 
were 3D printed and tested for antibiotic activity. The procedure described in Section
5.3.6 o f  the previous chapter was followed to measure antibiotic activity, and 5 discs 
were tested against each type o f  bacteria.
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5.3 Results and Discussion
5.3.1 Segmentation o f  Calcanei and Mirroring
Calcanei bones from the left and right foot were segmented and exported as STL 
files for 3D printing and for surface analysis. In Figure 5-11, dorsal and lateral view o f 
the right calcaneus are presented.
A B
Figure 5-11: 3D rendered view o f right calcaneus. A) Dorsal view. B) Lateral view.
The segmented calcanei, when visualized in the CT scan, give the best perspective 
o f  all the articulations with cuboid bone and the talus bone. This view can be seen in 
Figure 5-12. This view can be o f  great importance to a surgeon as it helps in planning the 
surgery. This particular CT scan has no factures, but any fractures present should be 
clearly evident, and having the 3D perspective improves the success rate o f  surgery.
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Figure 5-12: View o f segmented calcaneus in the foot showing its articulation with 
other bones in the CT scan data o f  the patient.
Similarly, the left calcaneus was segmented and exported as an STL file for 3D 
printing and analysis. Images o f a CAD-modelled left calcaneus are shown in F igure 
5-13.
A B
Figure 5-13: 3D rendered view o f left calcaneus bone. A) Dorsal view. B) Lateral 
view.
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Contralateral bones for both right and left calcanei were modeled in Blender 
software. The schematic representation o f  mirroring and modeling contralateral bones is 
illustrated in Figure 5-14.
A B C
Figure 5-14: Mirroring calcanei to model contralateral bones. A) Left calcaneus.
B) Mirrored left calcaneus. C) Right calcaneus.
The left calcaneus bone was imported into blender and a mirrored object was 
created. This object was similar to the contralateral calcaneus. Upon mirroring, all the 
faces o f  the object turned their plane normal to the inside o f the object. This caused the 
mirrored bone to be black, and contours were not clearly visible (as seen in Figure 5-14). 
The “Flip normal” feature o f the software was used to reset the normals o f the mirrored 
bone. Thus, the mirrored calcaneus bone was modeled and exported as an STL file.
5.3.2 3D Printing and 3D Scanning
Rafts and supports were used to 3D print the calcanei bones on a MakerBot 
Replicator 5th generation 3D printer. PLA filament was used to print the calcanei bones. 
The raft and supports that were attached to the body o f the 3D printed calcanei bones
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were carefully removed without causing any damage to the body o f the calcanei. The 3D 
printed bones were photographed, and are represented in F igure 5-15.
F igure 5-15: 3D printed calcanei bone using PLA. A and B- 3D printed right 
calcaneus. C and D- 3D printed left calcaneus.
These calcanei bones were 3D printed in PLA, a biodegradable polymer. They 
can be used in vitro with or without chemical modifications. PLA doped with GS retains 
its antibacterial properties after 3D printing [83]. Constructs with desired properties can 
be 3D printed with such versatile filaments. With advances in 3D printing every day, new 
materials that can be printed are increasing. One such interesting material is Polyvinyl 
Alcohol (PVA). PVA is a water soluble thermoplastic that can be used for 3D printing 
with fused deposition modeling. This polymer was crosslinked with aldehydes to make it 
water insoluble and improve its cytocompatibility [90]. Also, as the infill ratio can be 
varied, the empty spaces in the infill can be injected with hydrogels or bone cements to 
improve biological aspects o f  the constructs. Hybrid scaffolds would have the mechanical
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and structural advantage o f the strong PLA, but would also have the improved 
cytocompatibility o f hydrogels.
The 3D printed left calcaneus was 3D scanned using M akerBot Digitizer. The 3D 
printed bone was spray-coated with white paint to improve the scanner performance, as 
suggested by the manufacturer. The “Multiscan” feature was used to scan the object and 
export it as an STL file. The 3D scanned left calcaneus is shown in Figure 5-16. Only 
one 3D printed calcaneus was scanned as the objective was to measure the accuracy o f 
the 3D printer and 3D printing process.
A B
Figure 5-16: 3D scanned image o f  left calcaneus bone. A) Dorsal view.
B) Anterolateral view.
5.3.3 Topographical Analysis
The digital STL files for 3D objects represent primarily a wire frame comprised 
o f triangular meshes. In surface analysis, two meshes are laid on each other and deviation 
o f  every vertex is measured from the reference mesh. A graph is then displayed showing 
the percentage o f  vertices that deviate within a given range o f distance.
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5.3.3.1 CAD M odelled vs 3D Printed Calcaneus
The 3D printed left calcaneus was within 0.5 mm deviation for about 94.4% o f the 
CAD-modeled left calcaneus. CAD-modelled calcaneus was taken as reference model 
and compared with the 3D scanned calcaneus as a test model. The surface deviation 
analysis results from 3D Reshaper software are shown as a color map in Figure 5-17 
with the color legend on the left. A histogram next to color map is also displayed with the 
percentage o f  the surface within the deviations.
+00143*
Figure 5-17: Visual representation o f  comparison o f  CAD modelled vs 3D printed 
calcaneus bone.
93
About 99% o f the 3D printed calcaneus is congruent with the CAD-modeled 
calcaneus within a deviation o f  0.75 mm. A positive deviation indicates that the test 
model was above the reference surface, and a negative deviation indicate that the test 
model was below the reference model’s surface. Maximum deviation o f  1.3 mm above 
and 1.16 mm below the reference surface were observed. The largest deviations were 
observed in extra-articular facets o f the calcaneus bone. Deviation at articular surfaces is 
o f  primary importance as huge deviations can cause malunion and may require revisions, 
but the analysis reports suggest that articular surfaces were within 0.5 mm deviation. The 
largest deviations o f +1.3 mm and -1.16 mm were seen in the region o f  tarsal sinus beside 
the posterior talus articular surface. These results shows that the CAD-modeled and 3D 
printed objects are accurate to each other and demonstrate that commercially available, 
relatively inexpensive desktop printers can reproduce accurately.
5.3.3.2 CAD-Modelled Rieht Calcaneus v.v. M irrored Left Calcaneus
In this section o f topographical analysis, the original right calcaneus was taken as 
a reference while the mirrored left calcaneus was considered the test model. The original 
right calcaneus and the mirrored left calcaneus had 83.55% o f  the surfaces within 1 mm 
deviation. About 95.39% o f the total surface o f  the mirrored left calcaneus was within 1.5 
mm deviation with respect to the original surface deviations were observed in both intra- 
articular and extra-articular regions o f  the calcanei. The largest deviation o f 1.48 mm 
within articular surfaces was seen in the middle talar articular surface, shaded in orange 
color in Figure 5-18. The largest deviation o f  +2.75 mm and -2.29 mm were seen with 
respect to reference model. Regions showing the largest deviations were in the extra-
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articular facets o f calcaneus. The majority o f large deviations were observed in the 
tuberosity region o f  calcaneus, lateral and medial processes.
Figure 5-18: Topographical analysis o f right calcaneus and the mirrored left calcaneus.
5.3.3.3 CAD Modelled Left Calcaneus vs. M irrored R isht Calcaneus
About 83% o f the surface o f the original left and mirrored right calcanei were 
within 1 mm deviation, as shown in Figure 5-19. Deviations above ±1 mm were 
observed in both intra-articular and extra-articular regions o f the calcaneus. About 95.3% 
o f the total surface is within 1.5 mm deviation with respect to the reference model.
Within the intra-articular region’s largest deviation o f 1.59 mm was seen in the middle 
and anterior talar articulating facets. The largest deviations o f +2.31 mm and -2.79 mm 
were in the extra-articulate regions o f calcanei.
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Figure 5-19: Topographical analysis o f original left calcaneus and the mirrored right 
calcaneus.
These results were similar to the previous comparison o f  original right and 
mirrored left calcanei. Larger deviations were mostly in the extra-articular regions, 
especially in the medial and lateral processes o f  the calcaneus.
5.3.4 3D Printing CPCs
CPCs containing equimolar mixture o f  TTCP and DCPA with 10% w/v chitosan 
lactate were 3D printed on a Hyrel 3D printer. CPCs in the shape o f a dog bone and bar 
were 3D printed with 100% infill as shown in Figure 5-20.
Figure 5-20: Constructs 3D printed using CPCs. A) Dog bone shaped CPC. B) Bar 
shaped CPC. C) Bar shaped and dog bone shaped 3D printed CPCs.
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CPCs are non-Newtonian fluids; their viscosity increases with increasd shear.
This property is one o f  the complications that was observed while 3D printing CPCs. 
Also, when subjected to compression, the setting time o f CPCs is decreased. Faster 
setting o f  CPCs limits the printing time, and indirectly the volume o f bone cement that 
can be 3D printed. Hence, larger objects were not printed, and CPC printing was limited 
to smaller shapes like dog bone, bar and discs. Solution to overcome this limitation is to 
use an injectable and slow setting calcium cement formulations.
Another proposed solution to print larger objects is indirect 3D printing, as 
demonstrated by Park et al. (2014). Indirect 3D printing is a process where the CAD 
modeled files are created as negative molds. These molds can be filled with desired 
materials to obtain required shapes. It is called indirect 3D printing because 3D printing 
is used to create the required mold for the specimen, and the object o f interest is made by 
simple casting method. This method can be employed to create large size objects using 
CPCs o f any formulation [91].
CPCs with 1% wt. GS were 3D printed in the shape o f the discs, and their 
antibiotic activity was assayed using the agar diffusion method. Muller-Hinton agar 
plates were seeded with both gram negative and gram positive bacteria, E. coli and S. 
aureus. Good zones o f  inhibitions were observed against both types o f bacteria. Average 
zone o f  inhibition o f  4.52 ±0.1 cm in diameter were observed for CPC discs containing 
GS against E. coli as seen in Figure 5-21.
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Figure 5-21: M uller-Hinton agar plates inoculated with E. coli. A) E. coli with control 
CPC disc. B) E. coli with CPC discs added with 1% wt. GS.
Similar results were observed for gram positive bacteria, S. aureus. Average 
zones o f  inhibition were measured to be 4.19 ± 0.2 cm for 3D printed CPCs with GS. 
Clear zones o f inhibition were observed for test discs when compared to the control discs 
as seen in Figure 5-22.
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Figure 5-22: Muller- Hinton agar plates inoculated with S. aureus A) 3D printed 
control discs in S. aureus. B) 3D printed CPC discs with GS showing clear zones o f 
inhibition.
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As this 3D printing process did not involve heating, a wide range o f  drugs and/or 
growth factors can be added to bone cements to improve their bioactivity. Porosity o f  the 
3D printed object can be altered to meet the requirements using CAD modeling 
programs. Thus, 3D printing o f CPCs using this method can be o f  great significance in 
engineering patient specific bone grafts and implants.
5.4 Conclusions and Future W ork
From the results o f these experiments, we conclude that contralateral bones can be 
used as templates to print patient-specific bone grafts. A combination o f  tools can be used 
to process patient data from CT scans and to 3D printing grafts with desired internal 
architecture o f pores and infill. Commercially available 3D printers such as the MakerBot 
5th generation replicator can 3D print objects with accuracy o f  99% congruency within
0.75 mm deviation.
The calcaneus bone was used as an example to demonstrate that the contralateral 
bones had 83% topographical similarities within 1 mm deviation. The original bone and 
mirror imaged contralateral bones were compared topographically. This concept o f  using 
contralateral bones can also be applied in cranio-facial surgeries. In reconstructive 
surgeries involving the facial bones, 3D printed grafts can be used that are customized 
according to the patient’s need.
Methods for 3D printing o f  CPCs opens doors for new possibilities and research. 
As there is no element o f  heat (using EMO 25 printer head on Hyrel system 30M), a wide 
range o f  drugs, growth factors, and proteins can be incorporated into these 3D printed 
CPCs scaffolds. Creating three-dimensionally porous and strong scaffold is cardinal in
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tissue engineering bone grafts. Different 3D printing methods can enable us in fabricating 
such porous scaffolds.
CHAPTER 6 
CONCLUSIONS AND FUTURE WORK
The addition o f HNTs to CPCs was demonstrated to improve mechanical 
properties with compression strength in particular. Compression strength was observed 
upon the addition o f HNTs at 5% wt. concentration. Beyond this concentration, 
compression strength did not increase significantly. Results from cytocompatibility test 
suggest that the presence o f  HNTs in CPCs is not cytotoxic to cells. Further, chemical 
analysis suggests that presence o f HNTs may promote HA formation improving 
osteoconductivity. HNTs were able to induce differentiation in bone marrow stromal cells 
towards osteoblastic lineage.
Alginate hydrogels enhanced with CPCs and HNTs caused prominent changes in 
surface properties o f the hydrogels. Upon the addition o f HNTs, the surface o f alginate 
hydrogels was significantly modified. Increasing the roughness promotes better cell 
attachment and viability. Cytological assays demonstrated cytocompatibility o f  these 
novel hydrogels. Extended drug release from doped HNTs was studied for up to 48 hours. 
Clear zones o f  inhibition were observed in E. coli cultures inoculated with novel 
hydrogels fabricated.
The ability to use patient data from CT/MRI scans to model patient specific grafts 
and implants was demonstrated, and topographical similarities o f  contralateral bones was 
compared. Accuracy o f  inexpensive and commercially available desktop printer
1 0 0
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(Makerbot Replicator 5th generation) was evaluated. Economical methods to 3D print any 
CPC formulations were demonstrated on an inexpensive Hyrel system 30M 3D printer. 
As an example, CPCs loaded with antibiotics were 3D printed and shown to sustain 
antibiotic activity on gram positive and negative bacterial cultures. Patient specific grafts 
with desired biomaterials can be fabricated using 3D printing, thus enabling degradation 
rate and porosity to be controlled.
Since new methods are needed to meet patient-specific needs in the areas o f drug 
delivery and bone grafts, future work may use concepts from this research. Different 
biodegradable polymers can be used to 3D print grafts with various degrees o f  porosity, 
and can be seeded with cells. These 3D scaffolds can be cultured in vitro with patients’ 
cells to create a living graft. Such a living graft would be ideal, and close to autograft 
without the disadvantages o f autografts. CPCs with various formulations can be potential 
scaffolding biomaterials for bone tissue engineering.
APPENDIX A 
CELL CULTURES
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Protocol for culturing cells
Both the cell lines pre-osteoblasts and Bone marrow stromal cells need to be 
cultured through same protocol except for change in the media added. Pre-osteoblasts 
need to be added with is a-M EM  and for BSCs it is DMEM.
1. Turn on the UV light in the laminar flow hood and keep it for at least 15 minutes 
for sterilization process.
2. Turn on the blower and clean the hood with Cavicide.
3. All pipettes, reagents and transfer pipettes, cell culture dishes and pipettor should 
be sterile.
4. Remove complete media from the refrigerator and keep in incubator till it 
equilibrates to room temperature. This takes at least 30 minutes.
5. Wipe all the media bottles, reagents, pipettors, flasks, etc. with Cavicide before 
placing them inside the hood.
6. Cryovial from liquid nitrogen Dewar o f  mouse osteoblast is to be removed after 
step 5 and kept for thawing for not more than 1 minute. Place the vial in small 
beaker with pre equilibrated RO water. Turn the cap, only one quarter o f  it, in 
order to get rid o f  any trapped nitrogen.
7. Now place the vial in hood after wiping it with Cavicide and with Kim wipe.
8. Resuspend the contents o f  the vial using 5 ml pipette. Transfer it to cell culture T- 
25 flask. Add 10 mL o f complete a- MEM. Label the flasks and place in 
C 02incubator at 37°C.
9. M onitor the cell growth with inverted microscope for growth and change the 
medium after the cells have attached. Change the medium after three days.
10. Once the cells have reached 75-80% confluency, passage the cells by trypsinizing 
the cells. After trypsinizing the cells, centrifuge the cells and re-suspend the pellet 
in fresh medium after discarding the supernatant.
11. Measured volume o f cell suspension was added onto sterilized CPCs scaffolds 
and media was changed when color change was observed.
APPENDIX B 
HISTOCHEMICAL ASSAYS
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ALPase assay 
Solutions and buffers:
1. Dissolve one BCIP/NBT tablet (SigmaFast™ BC1P-NBT; Sigma Aldrich) in 10 
ml distilled water to prepare the substrate solution. Store in the dark and use 
within 2 hours.
2. Add 0.05% Tween 20 to Dulbecco’s PBS, w/o Ca++/ Mg++ (Cat. No. C-40232) 
to prepare the Washing Buffer.
Procedure:
1. Take the cells from the incubator and carefully aspirate the medium. Carefully 
wash the cells with PBS. Note: Do not disrupt the cell monolayer!
2. Carefully aspirate the PBS and transfer the tissue culture dish to a fume hood. 
Add enough 95% ethanol to cover the cellular monolayer.
3. After 60 seconds carefully aspirate the alcohol and wash the cells with Washing 
Buffer. Note: Longer fixation will lead to irreversible inactivation o f  AP.
4. Carefully aspirate the Washing Buffer and add enough BCIP/NBT substrate 
solution to cover the cellular monolayer. Incubate at room temperature in the 
dark for 5-10 minutes. Check staining progress every 2-3 minutes.
5. Wash the cells
6. Carefully aspirate the substrate solution and wash the cell monolayer with 
Washing Buffer. Carefully aspirate the Washing Buffer and add PBS.
7. Add enough volume o f 7% glacial acetic acid and incubate for 10 minutes, 
collect it and analyze using UV-Vis spectrophotometer
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